=> file caplus FILE 'CAPLUS' ENTERED AT 10:11:06 ON 02 MAR 2004 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.


FILE COVERS 1907 - 2 Mar 2004 VOL 140 ISS 10 FILE LAST UPDATED: 1 Mar 2004 (20040301/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d que

 $\Gamma8$ 

STR



G1 CN,NO2,C

Structure attributes must be viewed using STN Express query preparation.

L10 129 SEA FILE=REGISTRY SSS FUL L8

L11 47 SEA FILE=CAPLUS L10

=> d lll 1-47 ibib abs hitstr

L11 ANSWER 1 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2002:502305 CAPLUS

DOCUMENT NUMBER:

138:24620

TITLE:

Conformationally constrained 1,4-DHPs. A convenient

route to bis-1,4-DHPs as a novel class of nitrogen

compounds

AUTHOR(S):

Marchalin, Stefan; Chudik, Miloslav; Cvopova,

Katarina; Kozisek, Jozef; Lesko, Jan; Daich, Adam

CORPORATE SOURCE:

Faculty of Chemical Technology, Department of Organic

Chemistry, Slovak University of Technology,

10/022,874

SOURCE:

Bratislava, SK-812 37, Slovakia

Tetrahedron (2002), 58(28), 5747-5754

CODEN: TETRAB; ISSN: 0040-4020

Elsevier Science Ltd.

PUBLISHER: DOCUMENT TYPE:

LANGUAGE:

OTHER SOURCE(S):

GΙ

Journal English

CASREACT 138:24620

$$\mathbb{R}^2$$
 $\mathbb{R}^1$ 
 $\mathbb{C}^{CO_2Me}$ 
 $\mathbb{R}^1$ 
 $\mathbb{C}^{CHO}$ 
 $\mathbb{R}^1$ 

$$R^2$$
 $R^1$ 
 $R^2$ 
 $R^2$ 
 $R^2$ 
 $R^2$ 
 $R^2$ 
 $R^2$ 
 $R^2$ 
 $R^2$ 
 $R^3$ 
 $R^2$ 
 $R^3$ 
 $R^2$ 

On heating in glacial AcOH, 2-formyl-1,4-dihydropyridines I (R1 = MeCO, AΒ Me2CHO2C; R2 = 3-O2NC6H4, 5-nitro-2-furyl) underwent the tandem Knoevenagel condensation/aminonitrile cyclization with activated methylene reagents, such as Me acetoacetate or benzoylacetonitrile, to afford highly functionalized indolizines II (R3 = CN, MeO2C) in 65-88% yields. However, treatment of I (R1 = CN, MeCO, MeO2C, Me2CHO2C; R2 = 3-02NC6H4, 5-cyano-2-furyl, 2-thienyl, etc.) with 3-aminocrotonitrile gave the Knoevenagel condensation products, bis-1,4-dihydropyridines III, as the major products in 50-82% yields.

### IT212771-68-1P

RN

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of bis(dihydropyridine)s and indolizines via Knoevenagel condensation of dihydropyridines with active methylene compds.) 212771-68-1 CAPLUS

CN3-Pyridinecarboxylic acid, 5-acetyl-2-(dimethoxymethyl)-1,4-dihydro-6methyl-4-(5-nitro-2-furanyl)-, methyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT:

19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2001:88191 CAPLUS

DOCUMENT NUMBER:

134:280748

TITLE:

Facile access to 6-substituted 1,4,5,7-

tetrahydropyrrolo[3,4-b]-pyridines via Hantzsch type dimethyl 4-aryl-2-formyl-6-methyl-1,4-dihydropyridine-

3,5-dicarboxylates

AUTHOR(S):

Chudik, Milostav; Marchalin, Stefan; Knesl, Peter;

Daich, Adam; Decroix, Bernard

CORPORATE SOURCE:

Department of Organic Chemistry, Slovak University of

Technology, Bratislava, 812 37, Slovakia

SOURCE:

Journal of Heterocyclic Chemistry (2000), 37(6),

1549-1554

CODEN: JHTCAD; ISSN: 0022-152X

PUBLISHER:

HeteroCorporation

DOCUMENT TYPE:

Journal

LANGUAGE:

English

OTHER SOURCE(S):

CASREACT 134:280748

AB Efficient assembly of 6 title Me 6-R-2-methyl-5-oxo-4-(2-thienyl)-1,4,5,7-tetrahydropyrrolo[3,4-b]pyridine-3-carboxylates (R = allyl, cyclopropyl, cyclohexyl, cycloheptyl, 2-HOCH2CH2, 2-ClCH2CH2) 7a-f, resp., is described according to a Hantzsch type reaction from formyl-ester di-Me 2-formyl-6-methyl-4-(2-thienyl)-1,4-dihydropyridine-3,5-dicarboxylate 4 by imination, borohydride redn. and intramol. thermal amino-ester cyclization. The starting compd. 4 was prepd. in three steps from the readily available formyl deriv. 2-formylthiophene 1, Me 4,4-dimethoxy-3-oxobutanoate and Me 3-aminocrotonate.

IT 333352-81-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and acid hydrolysis of)

RN 333352-81-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-(dimethoxymethyl)-1,4-dihydro-6-methyl-4-(2-thienyl)-, dimethyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT:

14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

2000:626416 CAPLUS

DOCUMENT NUMBER:

133:317226

TITLE:

Deriving a Quantitative Chirality Measure from

Molecular Similarity Indices

AUTHOR(S):

Benigni, Romualdo; Cotta-Ramusino, Marina; Gallo, Grazia; Giorgi, Fabrizio; Giuliani, Alessandro; Vari,

Maria Rosaria

CORPORATE SOURCE:

Laboratorio di Tossicologia Comparata ed Ecotossicologia and Laboratorio di Chimica del Farmaco, Istituto Superiore di Sanita, Rome, 00161,

Italy

SOURCE:

Journal of Medicinal Chemistry (2000), 43(20),

3699-3703

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER:

American Chemical Society

DOCUMENT TYPE:

Journal

LANGUAGE:

English

A versatile new method has been developed as a continuous symmetry measure for chiral compds. The application of principal component anal. (PCA) to the complete N .times. N pairwise similarity matrixes (electrostatic potential and shape indexes) of a series of dihydropyridine calcium channel antagonists allowed to single out a chirality component and to compute a chirality score in terms of the between-enantiomers difference on the component value. The possibility to have chirality defined continuously at the series level could be of importance in eudismic analyses where the relative potency of two enantiomers is studied as well as in QSAR studies dealing with chiral mols. to improve the power of the generated models.

### 103069-24-5 IT

RL: PRP (Properties)

(deriving a quant. chirality measure from mol. similarity indexes using principal component anal. applied to dihydropyridine calcium channel antagonists in relation to QSAR)

RN 103069-24-5 CAPLUS

CN [4,4'-Bipyridine]-3,5-dicarboxylic acid, 2-[[2-(dimethylamino)ethoxy]methyl]-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{C-OMe} \\ \text{Me} \\ \text{HN} \\ \text{C-OEt} \\ \text{N} \\ \text{Me}_2\text{N-CH}_2\text{-CH}_2\text{-O-CH}_2 \\ \text{O} \end{array}$$

REFERENCE COUNT:

22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 4 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1999:745320 CAPLUS

DOCUMENT NUMBER: 132:122473

TITLE: A simple and expeditious synthesis of substituted

3-aminoindolizines

AUTHOR(S): Chudik, Miloslav; Marchalin, Stefan; Pham-Huu,

Duy-Phong; Humpa, Otakar; Friedl, Zdenek

CORPORATE SOURCE: Department of Organic Chemistry, Slovak Technical

University, Bratislava, SK-81237, Slovakia

SOURCE:

Monatshefte fuer Chemie (1999), 130(10), 1241-1252

CODEN: MOCMB7; ISSN: 0026-9247

PUBLISHER: Springer-Verlag Wien

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 132:122473

Treatment of easily available 2-formyl-1,4-dihydropyridines with 3-oxo-3-phenylpropanenitrile offers a simple and efficient one-pot method for the prepn. of substituted 3-aminoindolizines.

IT 256386-33-1P 256386-34-2P 256386-35-3P 256386-36-4P

> RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of substituted 3-aminoindolizines)

RN 256386-33-1 CAPLUS

CN3,5-Pyridinedicarboxylic acid, 2-(dimethoxymethyl)-1,4-dihydro-6-methyl-4-(5-nitro-2-furanyl)-, 5-ethyl 3-methyl ester (9CI) (CA INDEX NAME)

RN256386-34-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-(dimethoxymethyl)-1,4-dihydro-6-methyl-4-(5-nitro-2-furanyl)-, 3-methyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 256386-35-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-(dimethoxymethyl)-4-(2-furanyl)-1,4-dihydro-6-methyl-, 5-ethyl 3-methyl ester (9CI) (CA INDEX NAME)

RN 256386-36-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-(dimethoxymethyl)-4-(2-furanyl)-1,4-dihydro-6-methyl-, 3-methyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1999:739561 CAPLUS

DOCUMENT NUMBER:

132:180209

TITLE:

Force field and semiempirical MO conformational analysis of dihydropyridine calcium-channel

antagonists

AUTHOR(S):

Cotta Ramusino, M.; Vari, M. R.

CORPORATE SOURCE:

Laboratorio di Chimica del Farmaco, Istituto Superiore

SOURCE:

di Sanita, Rome, 00161, Italy THEOCHEM (1999), 492, 257-268

CODEN: THEODJ; ISSN: 0166-1280

PUBLISHER: DOCUMENT TYPE: Elsevier Science B.V.

Journal

LANGUAGE:

English

Force field and semiempirical MO calcns. were used to investigate the conformational features (dihydropyridine ring puckering, inter-ring and side-chain dihedral angles) of a group of 4-aryl substituted dihydropyridine calcium-channel antagonists. The considered compds. were studied both in vacuo and in water (simulated with the Cosmo approach). For derivs. bearing a basic side chain the corresponding protonated structures were also submitted to MO calcns. The investigation highlighted the conformational flexibility of the dihydropyridine derivs., the .DELTA. Hf of the most stable uncharged conformers of each compd. lying in a range of 2-7 kcal.cntdot.mol-1.

#### IT 259182-36-0 259182-52-0

RL: PRP (Properties)

(force field and semiempirical MO conformational anal. of dihydropyridine calcium-channel antagonists in neutral and protonated forms in vacuo and water)

259182-36-0 CAPLUS RN

[4,4'-Bipyridine]-3,5-dicarboxylic acid, 2-[[2-CN (dimethylamino)ethoxy]methyl]-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, (4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

259182-52-0 CAPLUS RN

[4,4'-Bipyridine]-3,5-dicarboxylic acid, 2-[[2-CN (dimethylamino)ethoxy]methyl]-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, conjugate monoacid, (4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

H+

REFERENCE COUNT:

THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 6 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1998:542395 CAPLUS

DOCUMENT NUMBER:

129:230605

TITLE:

Synthesis and spectral properties of methyl 6-acetyl-

or 6-cyano-3-amino-2-benzoyl-7-furyl-5-

methylindolizine-8-carboxylates

AUTHOR(S):

Chudik, Miloslav; Marchalin, Stefan; Havrilova,

Katarina

CORPORATE SOURCE:

Department of Organic Chemistry, Slovak Technical

University, Bratislava, 812 37, Slovakia

SOURCE:

Collection of Czechoslovak Chemical Communications

(1998), 63(6), 826-834

CODEN: CCCCAK; ISSN: 0010-0765

PUBLISHER:

Institute of Organic Chemistry and Biochemistry,

Academy of Sciences of the Czech Republic

DOCUMENT TYPE:

Journal

LANGUAGE:

English

Ι

GI

AB Good yields of the title compds. (I; X = COOMe, cyano, NO2; Y = MeCO, cyano) were obtained in the reaction of II (same X, Y) with 3-phenyl-3-oxopropanenitrile. Spectral properties of I were discussed.

IT 212771-64-7P 212771-65-8P 212771-66-9P 212771-67-0P 212771-68-1P 212771-70-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
 (prepn. and conversion to aldehyde)

RN 212771-64-7 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-acetyl-2-(dimethoxymethyl)-1,4-dihydro-4-[5-(methoxycarbonyl)-2-furanyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

RN 212771-65-8 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-cyano-2-(dimethoxymethyl)-1,4-dihydro-4-[5-(methoxycarbonyl)-2-furanyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

RN 212771-66-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-acetyl-4-(5-cyano-2-furanyl)-2- (dimethoxymethyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

RN 212771-67-0 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-cyano-4-(5-cyano-2-furanyl)-2- (dimethoxymethyl)-1,4-dihydro-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

RN 212771-68-1 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-acetyl-2-(dimethoxymethyl)-1,4-dihydro-6-methyl-4-(5-nitro-2-furanyl)-, methyl ester (9CI) (CA INDEX NAME)

RN 212771-70-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-cyano-2-(dimethoxymethyl)-1,4-dihydro-6-methyl-4-(5-nitro-2-furanyl)-, methyl ester (9CI) (CA INDEX NAME)

REFERENCE COUNT:

THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1998:414735 CAPLUS

DOCUMENT NUMBER:

129:67709

TITLE:

Dihydropyridine derivatives for treatment of benign

prostatic hyperplasia

INVENTOR(S):

Gluchowski, Charles; Wetzel, John M.; Chiu, George; Marzabadi, Mohammed R.; Wong, Wai C.; Nagarathnam,

Dhanapalan

PATENT ASSIGNEE(S):

SOURCE:

Synaptic Pharmaceutical Corporation, USA

U.S., 160 pp., Cont.-in-part of U.S. Ser. No. 166,367,

abandoned.

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

	PATENT NO.			KIND DATE		APPLICATION NO.					0.	DATE						
								US 1996-211764 1										
	MO	9422	829		A2	2	1994	1013		W	0 19	94-U	S385	2	1994	0405		
	WO	9422	829		A.	3	1995	0105										
		W:	AT,	ΑU,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CZ,	DE,	DK,	ES,	FI,	GB,	GE,
															MW,			
															US,			
		RW:													MC,			
			BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	ML,	MR,	NE,	SN,	TD,	TG	-	-
	zA	9402	360		Α		1995	0522		Z.	A 19	94-2	360		1994	0405		
	US	6211	198		В	1	2001	0403		U	s 19	98-9	8699		1998	0615		
	US	6310	076		В.	1	2001	1030		U	s 20	00-5	8897	3	2000	0607		
	US	2002	1935	99	A.	1	2002	1219		U	S 20	01-9	7280	1	2001	1005		
		6608					2003											
PRIO	RITY	APP:	LN.	INFO	. :				Į	JS 1	993-	4321	2	B2	1993	0405		
									Ţ	JS 1	993-	1201	69	В2	1993	0910		
									Ţ	JS 1	993-	1663	67	B2	1993	1210		
									Ţ	WO 1	994-1	US38.	52	W	19940	0405		
									Ţ	JS 1	993-	1663	80	Α	1993	1210		
									Ţ	JS 1	996-	2117	64	A3	19960	0223		
							•		Į	JS 1	998-	9869	9	А3	19980	0615		
							•		Ţ	JS 2	000-	5889	73	A3	20000	0607		

OTHER SOURCE(S):

MARPAT 129:67709

GI

$$R^{5}$$
 $R^{6}$ 
 $R^{6}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{8}$ 
 $R^{8}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{8}$ 
 $R^{8}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{6}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{8}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{5$ 

The dihydropyridine derivs. [I; R1 = linear or branched alkyl, alkoxyalkyl, aralkyl; R2, R4 = H, linear or branched alkyl; R3 = H, linear or branched alkyl, alkoxyalkyl, acyl; R5, R6 = H, OH, Cl, Br, F, NO2, CF3, cyano, NH2, etc.; R7, R8 = H, cyano, CF3, OH, alkoxy, etc.; Y = C1-5 alkylene, C4-8 alkylene interrupted by O, alkenylene, alkynylene, etc.; Z = O, NH, CH2], useful in treating benign prostatic hyperplasia, inhibition of cholesterol synthesis, and redn. in intraocular pressure, are prepd. and formulated. Amidation of carboxylic acid II (prepn. given) with 3-(4,4-diphenylpiperidino)propylamine in refluxing CH2Cl2 gave 58.8% title compd. (.+-.)-III, which showed Ki of 1.9 nmol/kg in reducing urethral pressure in vivo in dogs.

IT 166810-89-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of dihydropyridine derivs. as drugs)

RN 166810-89-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-acetyl-2-[(2-azidoethoxy)methyl]-4-(1,3-benzodioxol-5-yl)-1,4-dihydro-6-methyl-, 2-cyanoethyl ester (9CI) (CA INDEX NAME)

$$N_3$$
-  $CH_2$ -  $CH_2$ -  $O$ -  $CH_2$ -

REFERENCE COUNT:

THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1996:28492 CAPLUS

DOCUMENT NUMBER:

124:202067

TITLE:

Methods of synthesis of 4-(pyrazolyl)- and 4-(pyridyl)-5-oxo-1,4,5,7-tetrahydrofuro[3,4-

b]pyridines

AUTHOR(S):

Sausins, A.; Chekavichus, B.; Duburs, G. Latv. Inst. Org. Sint., Riga, Latvia

CORPORATE SOURCE: SOURCE:

Khimiya Geterotsiklicheskikh Soedinenii (1995), (7),

966-72

CODEN: KGSSAQ; ISSN: 0132-6244

PUBLISHER:

Latviiskii Institut Organicheskogo Sinteza

DOCUMENT TYPE:

Journal

LANGUAGE:

Russian

GI

$$R^{1}O_{2}C$$
 $N$ 
 $H$ 
 $I$ 

AB Title compds. I (R = 3-phenyl-1H-pyrazol-4-yl, 1,3-diphenyl-1H-pyrazol-4-yl, 3-pyridyl, 4-pyridyl; Rl = Me, Et, Pr, Bu, allyl, n-tetradecyl) were best prepd. from 4-chloro- and 4-acetoxyacetoacetate esters in variations of the Hantzsch synthesis with closure of the lactone ring in the process. IT 174314-92-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(4-(pyrazolyl)- and 4-(pyridyl)-5-oxo-1,4,5,7-tetrahydrofuro[3,4-b]pyridine prepn. methods)

RN 174314-92-2 CAPLUS

CN [3,4'-Bipyridine]-3',5'-dicarboxylic acid, 2'-[(acetyloxy)methyl]-1',4'-dihydro-6'-methyl-, 3'-ethyl 5'-methyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 9 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:888885 CAPLUS

DOCUMENT NUMBER: 124:227

TITLE: Structure-activity relationship studies in the field

of calcium antagonists. Xanthone 1,4-dihydropyridines

bearing a 2,3-lactone ring

AUTHOR(S): Rampa, A.; Budriesi, R.; Bisi, A.; Fabbri, G.; Barili,

P. L.; Chiarilni, A.; Valenti, P.

CORPORATE SOURCE: Department Pharmaceutical Sciences, University

Bologna, Italy

SOURCE: Arzneimittel-Forschung (1995), 45(9), 957-62

CODEN: ARZNAD; ISSN: 0004-4172

PUBLISHER: Cantor
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of xanthone 1,4-dihydropyridine derivs. bearing a 2,3-lactone ring and a 2-acetoxymethyl group were prepd. The compds. were evaluated for inotropic, chronotropic and calcium antagonist properties. The introduction of a 2,3-lactone ring improved the neg. inotropic activity and selectivity.

IT 171260-04-1P 171260-10-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. and structure activity of calcium antagonist xanthone dihydropyridines and cardiovascular effects)

RN 171260-04-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, diethyl ester (9CI) (CA INDEX NAME)

RN 171260-10-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methylene]-1,2,3,4-tetrahydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 3-ethyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

IT 171260-03-0P 171260-05-2P 171260-06-3P 171260-07-4P 171260-08-5P 171260-09-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and structure activity of calcium antagonist xanthone dihydropyridines and cardiovascular effects)

RN 171260-03-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 171260-05-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 3-ethyl 5-(2-propynyl) ester (9CI) (CA INDEX NAME)

AcO-CH<sub>2</sub> 
$$\stackrel{H}{N}$$
 Me

EtO-C
 $\stackrel{C}{\parallel}$   $\stackrel{C}{\circ}$   $\stackrel{C}$ 

RN 171260-06-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 3-ethyl 5-(2-propenyl) ester (9CI) (CA INDEX NAME)

AcO-CH<sub>2</sub> 
$$\stackrel{H}{\underset{N}{\bigvee}}$$
 Me

EtO-C  $\stackrel{C}{\underset{N}{\bigvee}}$  C-O-CH<sub>2</sub>-CH= CH<sub>2</sub>
 $\stackrel{C}{\underset{N}{\bigvee}}$  O

RN 171260-07-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 3-ethyl 5-(1-methylethyl) ester (9CI) (CA

INDEX NAME)

RN 171260-08-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methylene]-1,2,3,4-tetrahydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 171260-09-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methylene]-1,2,3,4-tetrahydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 3-ethyl 5-(2-propynyl) ester (9CI) (CA INDEX NAME)

L11 ANSWER 10 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:750506 CAPLUS

DOCUMENT NUMBER: 123:143638

TITLE: preparation of dihydropyridine derivatives as drugs INVENTOR(S): Gluchowski, Charles; Wetzel, John M.; Chiu, George;

Gluchowski, Charles; Wetzel, John M.; Chiu, George; Marzabadi, Mohammad R.; Wong, Wai C.; Nagarathnam,

Dhanapalan

PATENT ASSIGNEE(S): Synaptic Pharmaceutical Corp., USA

SOURCE: PCT Int. Appl., 760 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO.			KIND DATE		APPLICATION NO.					٥.	DATE						
	9422 9422	829		Α	2	1994	1013							1994	0405		
	W:	HU,	JP,	KG,	KΡ,	KR,	ΚZ,	LK,	LU,	LV,	CZ, MD,	MG,	MN,	MW,	NL,	NO,	NZ,
	RW:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	TT, IE, MR,	IT,	LU,	MC,	NL,	PT,	SE,
	9464	986		Α	1	1994	1024		Α	U 19	94-6	4986	-	1994	0405		
	9402 5767																
US	6211 6310	198		В	1	2001	0403		U	s 19	98-9	8699		1998	0615		
US	2002	1935	99	Α	1	2002	1219		U	S 20	00-5 01-9	8897. 7280:	3 1	2000	1005		
PRIORIT	6608 Y APP																
											1201 1663						
											1663 US38						
								Ţ	JS 1	996-	2117	64	А3	19960	0223		
											98699 5889						

OTHER SOURCE(S): MARPAT 123:143638

GI

$$R^{5}$$
 $R^{6}$ 
 $R^{1}$ 
 $R^{6}$ 
 $R^{7}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{1}$ 
 $R^{8}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{8}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{6}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{9}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{5}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{9}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{5}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{9}$ 
 $R^{1}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{5}$ 
 $R^{5$ 

Dihydropyridine derivs. [I; R1 = linear or branched alkyl, alkoxyalkyl, aralkyl; R2, R4 = H, linear or branched alkyl; R3 = H, linear or branched alkyl, alkoxyalkyl, acyl; R5, R6 = H, OH, Cl Br, F, NO2 CF3, cyano, NH2, etc.; R7, R8 = H, cyano, CF3, OH, alkoxy, etc.; Y = Cl-5 alkylene, C4-8 alkylene interrupted by O, alkenylene, alkynylene, etc.; Z = O, NH, CH2], useful in treating benign prostatic hyperplasia, inhibition of cholesterol synthesis, and redn. in intraocular pressure, are prepd. and formulated. Amidation of carboxylic acid II (prepn. given) with 3-(4,4-diphenylpiperidino)propylamine in refluxing CH2Cl2 gave 58.8% title compd. (.+-.)-III, which showed Ki of 1.9 nmol/kg in reducing urethral pressure in vivo in dogs.

## IT 166810-89-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of dihydropyridine derivs. as drugs)

RN 166810-89-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-acetyl-2-[(2-azidoethoxy)methyl]-4-(1,3-benzodioxol-5-yl)-1,4-dihydro-6-methyl-, 2-cyanoethyl ester (9CI) (CA INDEX NAME)

$$N_3 - CH_2 - CH_2 - O - CH_2 = O$$
 $C - O - CH_2 - CH_2 - CN$ 
 $Me$ 
 $Ac$ 

ACCESSION NUMBER:

1995:480292 CAPLUS

DOCUMENT NUMBER:

122:239545

TITLE:

Preparation of 4-bicyclyldihydropyridines as

cardiovascular agents.

INVENTOR(S):

Straub, Alexander; Goldmann, Siegfried; Stoltefuss, Juergen; Bechem, Martin; Dembrowsky, Klaus; Gross, Rainer; Hebisch, Siegbert; Huetter, Joachim; Rounding,

Howard-Paul

PATENT ASSIGNEE(S):

SOURCE:

Bayer A.-G., Germany Eur. Pat. Appl., 95 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

LANGUAGE:

Patent German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 630895	A1	19941228	EP 1994-109019	19940613
R: AT, BE,	CH, DE	, DK, ES,	FR, GB, GR, IE, IT, LI	, LU, MC, NL, PT, SE
DE 4321030	<b>A</b> 1	19950105	DE 1993-4321030	19930624
US 5545646	Α	19960813	US 1994-261585	19940617
CA 2126397	AA	19941225	CA 1994-2126397	19940621
JP 07033774	<b>A</b> 2	19950203	JP 1994-160800	19940621
US 5721248	Α	19980224	US 1996-644880	19960510
PRIORITY APPLN. INFO	.:		DE 1993-4321030	19930624
			US 1994-261585	19940617

OTHER SOURCE(S):

MARPAT 122:239545

GΙ

# \* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. [I; R1, R4 = H, amino, cyano, formyl, CF3, (substituted) alkyl; R2 = cyano, carbamoyl, alkoxycarbonyl, etc.; R3 = cyano, NO2, formyl, (substituted) alkoxycarbonyl, carbamoyl; R3R4 = COECH2; E = O, S, (CH2)n; n = 1,2; R5 = Q1-Q4, etc.; R24 = H, halo, alkyl, alkoxy; R25 = (cyclic) (unsatd.) (O- or S-interrupted) (substituted) hydrocarbyl; L = O, S, NH; V = O, S; X = N, NO], were prepd. having Ca agonist/antagonist activity (no data). Thus, Et 5-cyano-1,4-dihydro-2,6-dimethyl-4-(4-oxo-2-phenyl-4H-1-benzothiopyran-8-yl)-3-pyridinecarboxylate was heated with NaBH4 in Me3COH/MeOH to give title compd. II.

# IT 162135-33-3P 162135-36-6P 162135-37-7P 162135-44-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 4-bicyclyldihydropyridines as cardiovascular agents)

RN 162135-33-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(2-oxo-3-phenyl-2H-1-benzopyran-5-yl)-, 3-ethyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 162135-36-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(1-oxo-3-phenyl-1H-2-benzopyran-5-yl)-, 3-ethyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 162135-37-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(1-oxo-3-phenyl-1H-2-benzopyran-5-yl)-, diethyl ester (9CI) (CA INDEX NAME)

RN 162135-44-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(3-phenyl-1,6-naphthyridin-5-yl)-, 3-ethyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

L11 ANSWER 12 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1995:294115 CAPLUS

DOCUMENT NUMBER:

122:81143

TITLE:

Preparation of 2,6-disubstituted-4-

quinolyldihydropyridines for the treatment of heart

and circulatory diseases.

INVENTOR(S):

Stoltefuss, Juergen; Goldmann, Siegfried; Straub, Alexander; Bechem, Martin; Gross, Rainer; Hebisch,

Siegbert; Huetter, Joachim; Rounding, Howard-Paul

PATENT ASSIGNEE(S):

SOURCE:

Bayer A.-G., Germany

Eur. Pat. Appl., 29 pp.

DOCUMENT TYPE:

CODEN: EPXXDW Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 622364	A2		EP 1994-105774	19940414
EP 622364				III MG NI DE GE
DE 4313691	A1	19941103	DE 1993-4313691	, LU, MC, NL, PT, SE 19930427
AU 9459228	A1	19941103		19940331
US 5514803	Α	19960507	US 1994-230178	19940420
CA 2122001	AA	19941028	CA 1994-2122001	19940422
FI 9401909	Α	19941028	FI 1994-1909	19940425
NO 9401515	A	19941028	NO 1994-1515	19940426
JP 06340657	A2	19941213	JP 1994-110487	19940426
ZA 9402880	Α	19950104	ZA 1994-2880	19940426
HU 70487	A2	19951030	HU 1994-1190	19940426
CN 1100420	A	19950322	CN 1994-104698	19940427
PRIORITY APPLN. INFO.:			DE 1993-4313691	19930427
OTHER SOURCE(S):	MA	RPAT 122:81143	3	

$$R^2$$
 $R^4$ 
 $R^4$ 
 $R^5$ 

AB The title compds. [I; R1, R5 = H, CN, CHO, CF3, (un)branched alkyl, etc.; R2 = CN, NO2, CHO; R3 = (un)substituted C6-10 aryl, (un)substituted thienyl, (un)substituted pyridyl; R4 = (un)substituted aminocarbonyl, etc.; R1R2 = CO2CH2] (e.g., R1 = H, R2 = CN, R3 = Ph, R4 = CO2Pr, R5 = Me; m.p. 217-218.degree.), useful in the treatment of heart and circulatory diseases (no data), are prepd.

IT 160200-17-9P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of 2,6-disubstituted-4-quinolyldihydropyridines for the treatment of heart and circulatory diseases)

RN 160200-17-9 CAPLUS

CN 3-Pyridinecarboxylic acid, 5-acetyl-2-[(acetyloxy)methyl]-1,4-dihydro-4-(3-phenyl-5-quinolinyl)-, ethyl ester (9CI) (CA INDEX NAME)

# IT 160200-20-4P 160200-21-5P 160200-29-3P 160200-30-6P

Ι

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2,6-disubstituted-4-quinolyldihydropyridines for the treatment of heart and circulatory diseases)

RN 160200-20-4 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[(acetyloxy)methyl]-5-cyano-1,4-dihydro-6-methyl-4-(3-phenyl-5-quinolinyl)-, ethyl ester (9CI) (CA INDEX NAME)

RN 160200-21-5 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[(acetyloxy)methyl]-4-[3-(4-chlorophenyl)-5-quinolinyl]-5-cyano-1,4-dihydro-6-methyl-, ethyl ester (9CI) (CA INDEX NAME)

RN 160200-29-3 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[(2-aminoethoxy)methyl]-5-cyano-1,4-dihydro-6-methyl-4-(3-phenyl-5-quinolinyl)-, ethyl ester (9CI) (CA INDEX NAME)

RN 160200-30-6 CAPLUS

CN 3-Pyridinecarboxylic acid, 2-[(3-aminopropoxy)methyl]-5-cyano-1,4-dihydro-6-methyl-4-(3-phenyl-5-quinolinyl)-, 1-methylethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 13 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1995:257890 CAPLUS

DOCUMENT NUMBER: 122:31346

TITLE: Preparation of (5-quinolinyl)dihydropyridines and

(5-quinolinyl) furopyridines as cardiovascular agents Stoltefus, Juergen; Goldmann, Siegfried; Straub, Alexander; Bechem, Martin; Gros, Rainer; Hebisch, Siegbert; Huetter, Joachim; Rounding, Howard-Paul

PATENT ASSIGNEE(S):

SOURCE:

Bayer A.-G., Germany Ger. Offen., 35 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

INVENTOR(S):

Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA:	ГЕМТ NO.	KI	ND DATE	7	APPLICATION NO.	DATE			
DE	4313692	А	1 19941103	I	DE 1993-4313692	19930427			
AU	9459220	А	1 19941103	7	AU 1994-59220	19940331			
AU	675693	В	2 19970213						
EP	627427	А	1 19941207	F	EP 1994-105773	19940414			
		BE, CH,	DE, DK, ES,	FR, GB,	GR, IE, IT, I	I, LU, MC,	NL,	PT,	SE
US	5504210	A	19960402		JS 1994-230286		-	-	
CA	2121971	A	A 19941028		CA 1994-2121971	19940422			
FI	9401912	A	19941028	H	TI 1994-1912	19940425			
NO	9401516	A	19941028	1	IO 1994-1516	19940426			
JP	06329667	A	2 19941129	ت	IP 1994-110546	19940426			
HU	70486	A	2 19951030	ŀ	IU 1994-1188	19940426			
CN	1100419	A	19950322		N 1994-104689	19940427			
US	5550245	A	19960827	J	IS 1995-450461	19950525			
US	5629320	A	19970513	τ	S 1995-448930	19950525			
PRIORITY	APPLN.	INFO.:		DE 1	993-4313692	19930427			
				US 1	994-230286	19940420			
OMITTE GO	11D OF 101								

OTHER SOURCE(S): MARPAT 122:31346

GI

$$R^3$$
 $R^2$ 
 $R^4$ 
 $R^1$ 
 $R^1$ 
 $R^2$ 
 $R^3$ 
 $R^4$ 
 $R^4$ 
 $R^1$ 
 $R^4$ 
 $R^4$ 

AB Substituted (5-quinolinyl)dihydropyridines I (R1, R4 = H, alkyl, amino, etc.; R2 = aminocarbonyl group, aryl; R3 = cyano, nitro, etc.; R5 = alkyl, substituent, etc.) were disclosed. I are potential cardiovascular agents (no data). Example compds. are isppropyl 5-cyano-1,4-dihydro-2,6-dimethyl-4-[3-(phenylmethyl)-5-quinolinyl]-3-pyridinecarboxylate (II) and the Et 4-(3-phenoxy-5-quinolinyl)benzofuro[3,4-b]pyridine-3-carboxylate III.

IT 159795-79-6P

RN

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (quinolinyl)dihydropyridines cardiovascular agents)

159795-79-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(3-phenoxy-5-quinolinyl)-, diethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 14 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1995:214081 CAPLUS

DOCUMENT NUMBER:

122:10047

TITLE:

Preparation of circulation-active (dioxyalkylenearyl)dihydropyridines

INVENTOR(S): Franckowiak, Gerhard; Marhold, Albrecht; Bechem,

Martin; Gross, Rainer; Kayser, Michael; Schramm,

Matthias; Thomas, Guenther

PATENT ASSIGNEE(S):

Bayer A.-G., Germany

SOURCE:

U.S., 14 pp. Cont.-in-part of U.S. Ser. No. 814,213,

abandoned.
CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE		APPLICATION NO.	DATE
US 5344944	A	19940906		US 1993-116414	19930903
DE 3716652	A1	19881208		DE 1987-3716652	19870519
US 4886816	A	19891212		US 1988-190748	19880505
PRIORITY APPLN.	INFO.:		DE	1987-3716652	19870519
			US	1988-190748	19880505
			US	1989-431942	19891106
			US	1991-644857	19910122
			US	1991-814213	19911219

OTHER SOURCE(S):

CASREACT 122:10047; MARPAT 122:10047

GΙ

Title compds. I (R1 = H, NC, O2N, R7O2C wherein R7 = H, (substituted) C1-16 alkyl or cycloalkyl or alkenyl and optionally interrupted be O, S, bond; R2, R4 = C1-8 cycloalkyl, Ph, PhCH2, substituted C1-6 alkyl, etc.;R3 = H, (substituted) C1-4 alkyl optionally interrupted by O; R5 = C1-8 alkyl or cycloalkyl, R8O wherein R8 = H, C1-16 alkyl or alkenyl or cycloalkyl optionally interrupted by O and optionally substituted, etc.; R6 = substituted heterocyclyl) are prepd. Also prepd. was the intermediate 2,2-difluoro-4-formyl-1,3-benzodioxole. The activity of I was demonstrated by the influence of contraction force of the heart and tone of smooth muscle. Me .beta.-aminocrotonate and 2,2,3-trifluoro-1,4-benzodioxan-6-ylcarbaldehyde (prepn. given) were refluxed for 12 h to give I (R1 = MeO2C, R2 = R4 = Me, R3 = H, R5 = MeO, R6 = 2,2,3-trifluoro-1,4-benzodioxan-6-yl).

## IT 119895-50-0P

RN

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of circulation-active (dioxyalkylenearyl)dihydropyridines)

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(2,2,3-trifluoro-2,3-dihydro-1,4-benzodioxin-5-yl)-, diethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 15 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1994:680509 CAPLUS

DOCUMENT NUMBER:

121:280509

TITLE:

AUTHOR(S):

Synthesis of thiophenyl isosteres of

1,4-dihydropyridines with calcium antagonist activity

Falsone, G.; DeNardo, M. M.; Cateni, F.; Bet, N.;

Kukovez, W. R.; Holzmann, S.; Stadtthaller, A.

CORPORATE SOURCE:

Department of Pharmaceutical Sciences, University of

Trieste, Trieste, I-34127, Italy

Pharmaceutical and Pharmacological Letters (1994),

3(6), 233-6

CODEN: PPLEE3; ISSN: 0939-9488

DOCUMENT TYPE:

LANGUAGE:

SOURCE:

GΙ

Ι

Me EtO<sub>2</sub>C CO2Et Me

The synthesis of the thiophenyl isosteres of 1,4-dihydropyridines from AB 3-methyl-2-thiophenecarboxaldehyde and Me acetoacetate in presence of ammonia is described. The derivs., e.g. I (R = CH2OH), contg. various substituents at the 2-position of the pyridine ring, are obtained via the key intermediate I (R = CHO). The compds. tested showed less calcium antagonist activity than nifedipine.

IT158778-14-4P

> RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of thienyldihydropyridines with calcium antagonist activity)

RN 158778-14-4 CAPLUS

3,5-Pyridinedicarboxylic acid, 2-(diethoxymethyl)-1,4-dihydro-6-methyl-4-CN (3-methyl-2-thienyl)-, diethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 16 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 19

1994:605366 CAPLUS

DOCUMENT NUMBER:

121:205366

TITLE:

[[[(sulfonylamino)carboazolyl]alkoxy]ethoxymethyl]pyri

dinedicarboxylates as antihypertensives

>INVENTOR(S):

Niewoehner, Ulrich; Knorr, Andreas; Perzborn,

Elisabeth; Schramm, Matthias; Schlemmer, Karl-Heinz

PATENT ASSIGNEE(S):

SOURCE:

Bayer A.-G., Germany

Ger. Offen., 17 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
		<u>-</u>		
DE 4305456	A1	19940825	DE 1993-4305456	19930223
PRIORITY APPLN. INFO.	:	DE	1993-4305456	19930223
OTHER SOURCE(S):	MA	RPAT 121:205366		

GΙ

AB The title compds. were disclosed antihypertensives, for treatment of coronary insufficiency, ischemia, prevention of stenosis and treatment of arteriosclerosis, asthma and allergies. An example compd., the [[[[(phenylsulfonyl)amino]carboazolyl]propyl]amino]ethoxy]dihydropyridine dicarboxylate I was prepd. In rats I (3 mg/kg) had an antihypertensive effect.

## IT 158152-18-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological

study); PREP (Preparation); USES (Uses)

(prepn. of [[[(sulfonylamino)carboazolyl]alkoxy]ethoxymethyl]pyridinedicarboxylates antihypertensives)

RN 158152-18-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2-[[2-[[3-[3-[(4-fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazol-9-yl]-1-oxopropyl]amino]ethoxy]methyl]-1,4-dihydro-6-methyl-, 3-ethyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

PAGE 1-A

PAGE 2-A

L11 ANSWER 17 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1994:435279 CAPLUS

DOCUMENT NUMBER:

121:35279

TITLE:

SAR studies in the field of Ca-antagonists:

2-substituted 1,4-dihydropyridines with a xanthone

backbone

AUTHOR(S):

Bisi, Alessandra; Budriesi, Roberta; Chiarini,

CORPORATE SOURCE:

Alberto; Rampa, Angela; Valenti, Piero

CORPORATE SOURCE

Dip. Sci., Univ. Stud. Bologna, Bologna, 40126, Italy

SOURCE:

Farmaco (1993), 48(11), 1491-502 CODEN: FRMCE8; ISSN: 0014-827X

DOCUMENT TYPE:

Journal

LANGUAGE:

English

GΙ

$$R^{1}O_{2}C$$
  $CO_{2}R^{2}$   $Me$   $N$   $R$   $I$ 

AB A series of 2-substituted 1,4-dihydropyridines I [R = CH2F, NH2, CH2O(CH2)2NH2; R1 = Me, Et; R2 = Me, Et, CHMe2, allyl] with a xanthone backbone was prepd. The compds. were evaluated for inotropic, chronotropic and calcium antagonist properties.

IT 155602-20-3P 155602-21-4P 155602-22-5P

155602-23-6P 155602-24-7P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and inotropic, chronotropic and calcium antagonist properties of)

RN 155602-20-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-1,4-dihydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 5-ethyl 3-methyl ester (9CI) (CA INDEX NAME)

RN 155602-21-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-1,4-dihydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, diethyl ester (9CI) (CA INDEX NAME)

RN 155602-22-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-1,4-dihydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 5-ethyl 3-(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 155602-23-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-1,4-dihydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 5-ethyl 3-(2-propenyl) ester (9CI) (CA INDEX NAME)

$$H_2N-CH_2-CH_2-O-CH_2$$
 $H_2C=CH-CH_2-O-C$ 
 $C-OEt$ 
 $O$ 

RN 155602-24-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-1,4-dihydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 5-ethyl 3-(2-propynyl) ester (9CI) (CA

INDEX NAME)

$$\begin{array}{c} \text{H}_2\text{N}-\text{CH}_2-\text{CH}_2-\text{O}-\text{CH}_2 & \overset{\text{H}}{\text{N}} & \text{Me} \\ \\ \text{HC} = \text{C}-\text{CH}_2-\text{O}-\text{C} & \overset{\text{C}}{\text{C}}-\text{OEt} \\ & & \text{O} \\ \\ & & \text{O} \\ \end{array}$$

IT 155602-25-8P

> RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and ring cleavage of)

RN155602-25-8 CAPLUS

CN3,5-Pyridinedicarboxylic acid, 2-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2yl)ethoxy]methyl]-1,4-dihydro-6-methyl-4-(9-oxo-9H-xanthen-4-yl)-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 18 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1990:35873 CAPLUS

DOCUMENT NUMBER:

112:35873

TITLE:

Preparation of 4-(2,1,3-benzoxadiazol-4-yl)-2-

carbamoyloxymethyl-1,4-dihydropyridine-3,5-

dicarboxylates as cardiovascular agents

INVENTOR(S):

Iwazawa, Zenichi; Fukami, Takehiro; Nagura, Jun;

Fukuroda, Naohiro

PATENT ASSIGNEE(S):

Banyu Pharmaceutical Co., Ltd., Japan

SOURCE:

Jpn. Kokai Tokkyo Koho, 9 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

Patent Japanese

LANGUAGE:

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE \_\_\_\_\_ JP 01168684 A2 19890704 JP 1987-327698 19871224 PRIORITY APPLN. INFO.: JP 1987-327698 19871224 OTHER SOURCE(S): MARPAT 112:35873 GT

$$\begin{array}{c|c} & & & \\ & & & \\ R^2o_2C & & & \\ & & & \\ Me & & & \\ & & & \\ N & & \\ & & & \\ R^1 & & \\ & & & \\ \end{array}$$

AΒ The title derivs. [I; R1 = H, lower alkyl; R2, R3 = lower alkyl, lower alkoxyalkyl, (CH2) nNR6R7; n = 2-4; R4, R5 = H, lower alkyl; R6, R7 = loweralkyl, aralkyl, aryl] and their pharmaceutically acceptable acid addn. salts are prepd. I have strong vasodilating and antihypertensive activity with reduced side effects such as increase in heart beats, and thus are useful for treatment of cardiovascular diseases such as hypertension, heart failure, angina pectoris, and cardiac infarction. Thus, a soln. of 4-formyl-2,1,3-benzoxadiazole, AcOCH2CH2COCH2CO2CHMe2, and MeC(NH2):CHCO2Me in 2-propanol was refluxed 12 h to give, after deacetylation with MeONa in MeOH, iso-Pr H-(2,1,3-benzoxadiazol-4-yl)-1,4dihydro-2-hydroxymethyl-5-methoxycarbonyl-6-methyl-3-pyridinecarboxylate which was stirred with ClSO2NCO in benzene to give I (R1 = R4 = R5 = H, R2 = Me, R3 = iso-Pr)(II). II showed smooth muscle relaxant activity in house rabbit superior mesenteric artery with ED50 of (4.0 .+-. 1.5).times. 10-10 M and at 7.5 mg/kg p.o. lowered 20% the blood pressure of spontaneously hypertensive rats.

IT 124465-32-3P 124465-33-4P 124465-34-5P 124465-35-6P 124465-36-7P 124465-37-8P 124465-38-9P 124465-39-0P 124484-11-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of, as cardiovascular agent)

RN 124465-32-3 CAPLUS

CN

3,5-Pyridinedicarboxylic acid, 2-[[(aminocarbonyl)oxy]methyl]-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-6-methyl-, 5-methyl 3-(1-methylethyl) ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & \\ \parallel & \\ H_2N-C-O-CH_2 & H \\ \hline i-PrO-C & C-OMe \\ \parallel & 0 & O \\ \hline \end{array}$$

RN 124465-33-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2-methyl-6-[[[(methylamino)carbonyl]oxy]methyl]-, 3-methyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 124465-34-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2[[[(dimethylamino)carbonyl]oxy]methyl]-1,4-dihydro-6-methyl-,5-methyl
3-(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 124465-35-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[(aminocarbonyl)oxy]methyl]-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-6-methyl-, diethyl ester (9CI) (CA INDEX

10/022,874

NAME)

$$\begin{array}{c|c} O \\ H_2N-C-O-CH_2 \\ EtO-C \\ O \\ O \\ O \\ N \\ N \end{array}$$

RN 124465-36-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2-methyl-6-[[[(methylamino)carbonyl]oxy]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

RN 124465-37-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[(aminocarbonyl)oxy]methyl]-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-6-methyl-,5-methyl 3-[2-[methyl(phenylmethyl)amino]ethyl] ester (9CI) (CA INDEX NAME)

CN 3,5-Pyridinedicarboxylic acid, 2-[[(aminocarbonyl)oxy]methyl]-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-6-methyl-, 5-methyl 3-[2-[methyl(phenylmethyl)amino]ethyl] ester, hydrochloride (9CI) (CA INDEX NAME)

•x HCl

RN 124465-39-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-1,2-dimethyl-6-[[[(methylamino)carbonyl]oxy]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

RN 124484-11-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[(aminocarbonyl)oxy]methyl]-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-6-methyl-, 5-(2-methoxyethyl) 3-(1-methylethyl) ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} O & \\ H_2N-C-O-CH_2 & H & Me \\ \hline \\ i-PrO-C & C-O-CH_2-CH_2-OMe \\ \hline \\ O & O \\ \hline \\ \end{array}$$

IT 124465-40-3P 124465-43-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as intermediate for cardiovascular agent)

RN 124465-40-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-6-methyl-, 5-methyl 3-(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 124465-43-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[(aminocarbonyl)oxy]methyl]-4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-6-methyl-, 3-(2-chloroethyl) 5-methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & O \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\
 & | \\$$

CAPLUS COPYRIGHT 2004 ACS on STN L11 ANSWER 19 OF 47

ACCESSION NUMBER: 1989:154161 CAPLUS

DOCUMENT NUMBER: 110:154161

TITLE: Preparation of [(alkylenedioxy)aryl]dihydropyridines

as cardiovascular agents

INVENTOR(S): Franckowiak, Gerhard; Marhold, Albrecht; Bechem,

Martin; Gross, Rainer; Kayser, Michael; Schramm,

Matthias; Thomas, Guenther

PATENT ASSIGNEE(S):

SOURCE:

Bayer A.-G., Fed. Rep. Ger.

Eur. Pat. Appl., 32 pp. CODEN: EPXXDW

DOCUMENT TYPE:

Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 291799	A2	19881123	EP 1988-107382	19880507
EP 291799	A3	19891220		
EP 291799	B1	19930616		
R: AT, BE,	CH, DE	ES, FR, GB,	IT, LI, NL, SE	
DE 3716652	A1	19881208	DE 1987-3716652	19870519
AT 90676	E	19930715	AT 1988-107382	19880507
ES 2058173	Т3	19941101	ES 1988-107382	19880507
JP 63303980	A2	19881212	JP 1988-119453	19880518
JP 2558326	B2	19961127		
JP 08245613	A2	19960924	JP 1995-289429	19951011
JP 2721822	В2	19980304		
PRIORITY APPLN. INFO.	:	DI	E 1987-3716652	19870519
•		El	P 1988-107382	19880507
OTHER SOURCE(S):	MAI	RPAT 110:15416		,

GΙ

$$R^{1}$$
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{4}$ 
 $R^{2}$ 
 $R^{2}$ 
 $R^{2}$ 
 $R^{3}$ 
 $R^{4}$ 
 $R^{4}$ 

AΒ The title compds. [I; R1 = H, cyano, NO2, (un) substituted CO2H; R2, R4 = HCO, cyano, Ph, PhCH2, (un) substituted alkyl, cycloalkyl; R3 = H, (un) substituted alkyl, alkoxyalkyl; R5 = alkyl, OR8, R8 = H, (un) substituted alkyl; R6 = alkylenedioxyphenyl group Q; X = bond, CHF,

RN

CF2] were prepd. R6CH:NBu (R6 = 2,2,3-trifluoro-1,4-benzodioxan-5-yl) was stirred 24 h with AcOCH2COCH2CO2Et in Ac2O to give R6CH:C(CO2Et)COCH2OAc which was refluxed 6 h with H2NCMe: CHCO2Et in EtOH to give title compd. II (R = Et, R4 = CH2OAc). II (R = R4 = Me) gave a 100% redn. in ventricular contractile amplitude of isolated perfused guinea pig heart at 10-3 g/L.

TΤ 119895-50-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as cardiovascular agent)

119895-50-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(acetyloxy)methyl]-1,4-dihydro-6-methyl-4-(2,2,3-trifluoro-2,3-dihydro-1,4-benzodioxin-5-yl)-, diethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 20 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1989:114650 CAPLUS

DOCUMENT NUMBER: 110:114650

TITLE: Long acting dihydropyridine calcium antagonists. 2.

2-[2-aminoheterocycloethoxy] methyl derivatives

AUTHOR(S): Arrowsmith, John E.; Campbell, Simon F.; Cross, Peter

E.; Burges, Roger A.; Gardiner, Donald G.

CORPORATE SOURCE: Dep. Discovery Chem., Pfizer Cent. Res.,

Sandwich/Kent, CT13 9NJ, UK

SOURCE: Journal of Medicinal Chemistry (1989), 32(3), 562-8

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 110:114650

GT

As series of title compds. were prepd. as selective coronary vasodilators. Thus, condensation of I [R = H; X = 2-, 3-Cl, 2,3-Cl2, 2,3-Cl(F3C)] with (MeS)2C:NCN gave I [R = C(:NCN)SMe], which cyclized with compds. such as N2H4, to give compds. such as II. Approx. 25 compds. were prepd. A wide variety of five- and six-membered heterocycles were acceptable at the 2-position of the dihydropyridine ring and in vitro potency and tissue selectivity was independent of the basicity of these heterocycles. The SAR indicated that activity was optimum when the largest ester group was placed at the 3 rather than 5 position. II (X = 2,3-Cl2) emerged as a potent (IC50 = 6.3 .times. 10-9 M) and tissue-selective calcium channel blocker with a duration of action >7 h in the anesthetized dog.

II

#### IT 103198-59-0

RL: RCT (Reactant); RACT (Reactant or reagent) (condensation of, with imidodithiocarbonates)

RN 103198-59-0 CAPLUS

CN [3,4'-Bipyridine]-3',5'-dicarboxylic acid, 2'-[(2-aminoethoxy)methyl]-2-chloro-1',4'-dihydro-6'-methyl-, 3'-ethyl 5'-methyl ester (9CI) (CA INDEX NAME)

### IT 118070-93-2P

RN

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and coronary vasodilating activity of) 118070-93-2 CAPLUS

CN [3,4'-Bipyridine]-3',5'-dicarboxylic acid, 2'-[[2-[(5-amino-1H-1,2,4-triazol-3-yl)amino]ethoxy]methyl]-2-chloro-1',4'-dihydro-6'-methyl-, 3'-ethyl 5'-methyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 21 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1989:108190 CAPLUS

DOCUMENT NUMBER:

110:108190

TITLE:

New piperidines, their preparation, and drugs

containing them for treatment of heart and circulation

disorders

INVENTOR(S):

Flockerzi, Dieter; Amschler, Hermann; Eistetter,

Klaus; Eltze, Manfrid; Klemm, Kurt; Kolassa, Norbert;

Sanders, Karl; Schudt, Christian; Ulrich, Wolf

Ruediger

PATENT ASSIGNEE(S):

Byk Gulden Lomberg Chemische Fabrik G.m.b.H., Fed.

Rep. Ger.

SOURCE:

PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 8801266	<b>A</b> 1	19880225	WO 1987-EP437	19870810
W: AU, DK,	FI, HU	, JP, KR, NO,	US	
RW: AT, BE,	CH, DE	, FR, GB, IT,	LU, NL, SE	
AU 8778100	A1	19880308	AU 1987-78100	19870810
PRIORITY APPLN. INFO.	.:		СН 1986-3265	19860814
			WO 1987-EP437	19870810
OTHER SOURCE(S):	MA	RPAT 110:1081	90	, 0010
GI				

$$R^{3}O_{2}C$$
 $R^{2}$ 
 $CO_{2}R^{1}$ 
 $CH_{2}OAN$ 
 $R^{5}$ 
 $R^{6}$ 
 $R^{7}$ 
 $R^{8}$ 
 $R^{8}$ 
 $R^{8}$ 
 $R^{1}$ 
 $R^{8}$ 
 $R^{1}$ 
 $R^{8}$ 
 $R^{1}$ 
 $R^{8}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{1}$ 

AΒ Piperidines I [R1, R3 = C1-6 alkyl, C3-7 alkoxyalkyl; R2 = H, R1; R4 = II; R5, R6 = aryl; R7, R8 = H, OH, NO2, halo, cyano, F3C, C1-4 alkyl, C1-4 (fluorinated) alkoxy, C1-4 alkoxycarbonyl, C2-5 acyl, (mono- or dialkyl)amino; Y = O, S, CH:CH, CH:N, III, IV; A = C2-6 alkylene] are prepd. for use as vasodilators, antihypertensives, smooth muscle relaxants, saliuretics, antithrombotics, and hemorheol. agents. I [R1 = Et; R2 = R3 = Me; R4 = 3-02NC6H4; R5 = R6 = Ph; A = (CH2)3] (V), administered to spontaneously hypertensive rats at 10 .mu.mol/kg/day for 4 days, diminished the blood pressure by 46% after 2 h and 23% after 24 h. To prep. V-HCl, 3-(4,4-diphenyl-1-piperidyl)propanol was O-alkylated with Et 4-chloroacetoacetate, the product was treated with NH3 to produce Et 3-amino-3-[3-(4,4-diphenyl-1-piperidinyl)propoxymethyl] crotonate, and this compd. was refluxed in Me3COH with Me 2-acetyl-3-(3-nitrophenyl)acrylate. IT

119371-79-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of, as antihypertensive)

RN119371-79-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[3-(4,4-diphenyl-1piperidinyl)propoxy]methyl]-1,4-dihydro-4-isoxazolo[4,5-c]pyridin-4-yl-6methyl-, 3-ethyl 5-methyl ester, hydrochloride (9CI) (CA INDEX NAME)

●x HCl

## 10/022,874

DOCUMENT NUMBER:

109:92816

TITLE:

Preparation of 4-phenyldihydropyridine-3,5-

dicarboxylates as calcium antagonists

INVENTOR(S):

Peglion, Jean Louis; Gargouil, Yves Michel; Vilaine,

Jean Paul

PATENT ASSIGNEE(S):

Adir et Compagnie, Fr.

SOURCE:

Fr. Demande, 49 pp.

CODEN: FRXXBL

DOCUMENT TYPE:

Patent

LANGUAGE:

French

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2602231 FR 2602231			FR 1986-11260	19860804
CA 1338637	B1 A1	19881028	CA 1987-542335	19870716
AU 8776505		19880211	AU 1987-76505	
	B2	19900329	AU 1907-70303	19070003
JP 63041460		19880222	JP 1987-194274	19870803
ZA 8705727	A			
US 4870091	А	19890926	US 1987-81303	
DK 8704065	A		DK 1987-4065	
EP 259206	A1	19880309	EP 1987-401808	19870804
EP 259206	B1	19911009		
		, FR, GB, IT, 1	LI, LU, NL, SE	
ES 2004467			ES 1987-2288	19870804
			AT 1987-401808	19870804
			US 1989-386430	19890727
US 5026863	Α	19910625	US 1990-518019	19900502
PRIORITY APPLN. INFO.	. :	FI	R 1986-11260	19860804
		US	5 1987-81303	19870803
		EI	9 1987-401808	19870804
		FI	R 1989-8920	19890704
		US	5 1989-386430	19890727
OTHER SOURCE(S):	CA	SREACT 109:9283	l6; MARPAT 109:928	16

Ι

$$\begin{array}{c|c} \text{Ar} & \text{CO}_2\text{CHYZ} \\ & \text{W} & \text{N} & \text{U}\left(\text{CH}_2\right)_m\text{V}\left(\text{CH}_2\right)_n\text{NR}^1\text{R}^2 \end{array}$$

AB The title compds. [I, Ar = (un)substituted Ph; R1, R2 = H, alkyl, alkylene, phenylalkyl, etc.; U = CH2O, CH2CH2O, CH2; V = O, CH2; W = alkyl, alkoxymethyl; Y, Y1, Z, Z1 = H, alkyl, cyclopropyl, dicyclopropylmethyl, 2,2-dicyclopropylethyl, etc.; m, n = 1-4] were prepd. RCH2CH2CH2CH2CH2 (R = N-phthalimido) was added to THF contg. NaH followed by ClCH2COCH2CO2Et and the mixt. left overnight to give RCH2CH2CH2CH2COCH2COCH2CO2Et (R as above) which was refluxed overnight with C6F5CHO and MeC(NH2):CHCO2Me in Me2CHOH to give phenyldihydropyridinedicarboxylate II (R as above). The latter was stirred 3 h with H2NNH2 in EtOH to give II (R = NH2) (III) which gave a 71 mm lowering of systolic arterial pressure in spontaneously hypertensive rats 24 h after an oral dose of 3 mg III/kg. Gelatin-coated tablets were prepd. each contg. III hemifumarate 2, starch 15, lactose 25, and talc 5 mg.

## IT 115972-85-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn., as calcium antagonist)

RN 115972-85-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[2-(2-aminoethoxy)ethoxy]methyl]-4-(1,3-benzodioxol-4-yl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 23 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1988:131592 CAPLUS

DOCUMENT NUMBER:

108:131592

TITLE:

Preparation of 1,4-dihydropyridine derivatives as

antihypertensives

INVENTOR(S):

Archibald, John Leheup; Ward, Terence James; Opalko,

Albert

PATENT ASSIGNEE(S):

John Wyeth and Brother Ltd., UK

SOURCE:

Brit. UK Pat. Appl., 13 pp.

CODEN: BAXXDU

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2185982	A1	19870805	GB 1987-2016	19870129
GB 2185982	B2	19900516		
AT 129242	E	19951115	AT 1987-300785	19870129
ES 2078215	Т3	19951216	ES 1987-300785	19870129
HU 45988	A2	19880928	HU 1987-311	19870130
ни 199139	В	19900129		

CA 1329600	A1	19940517	CA 1987-528568	19870130
JP 62201868	A2	19870905	JP 1987-21651	19870131
JP 07023370	B4	19950315		
US 5064842	Α	19911112	US 1990-544097	19900625
PRIORITY APPLN. INFO.:		G	B 1986-2518	19860201
		U	S 1987-7684	19870128
		U	S 1989-309018	19890207
OTHER SOURCE(S):	C	ASREACT 108:131	592	

OTHER SOURCE(S):

GΙ

Ι

$$R^{1}O_{2}C$$
 Ar  $CO_{2}R^{2}$   $CO_{2}R^{2}$   $CO_{2}R^{2}$ 

The title compds. I [Z1Z2 = bond, when Z3 is an electron withdrawing AB group, Z2 can also represent OH and Z1 can represent H; Ar = (un) substituted aryl; R = H, (un) substituted alkyl, aralkyl; R1, R2 = H, (un) satd., (un) substituted cyclic or acyclic aliph. hydrocarbon residue; A = XR3 wherein X = (CHR6)pY(CHR7)q, Y = O, S, NR8, bond, p, q = O-2, R6-R8 = H, alkyl, R3 = (un)substituted heteroaryl; Z3 = haloalkyl, (un) substituted Ph, CN, CHO, etc.], useful as antihypertensives (no data), were prepd. A mixt. of Me 3-amino-4-fluoro-2-butenoate, 3-(NO2)C6H4CHO, and Et 4-(imidazol-1-yl)acetoacetate in EtOH was refluxed for several h to give 1,4-dihydro-2-fluoromethyl-6-(imidazol-1-ylmethyl)-4-(3nitrophenyl)pyridine-3,5-dicarboxylic acid 3-Me 5-Et diester.

#### ΙT 113514-01-5P

CN

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as antihypertensive)

RN 113514-01-5 CAPLUS

> 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2-(dimethoxymethyl)-1,4-dihydro-6-(1H-imidazol-1-ylmethyl)-, 5-ethyl 3-methyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 24 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN ACCESSION NUMBER: 1988:75226 CAPLUS

DOCUMENT NUMBER:

108:75226

TITLE:

Preparation of 4-phenyldihydropyridine-3,5-

INVENTOR(S):

dicarboxylates as calcium channel blockers Baxter, Andrew John Gilby; Dixon, John; Mcinally,

Thomas; Tinker, Alan Charles

PATENT ASSIGNEE(S):

Fisons PLC, UK

SOURCE:

GΙ

Eur. Pat. Appl., 77 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 225175 EP 225175	A2 A3	19870610 19881228	EP 1986-309244	19861127
			GB, GR, IT, LI, LU, NL,	SE
JP 62187453	A2	19870815	JP 1986-280953	19861127
PRIORITY APPLN. INFO.	. :		GB 1985-29301	19851128
			GB 1985-29786	19851203
			GB 1985-29787	19851203
			GB 1986-4421	19860221
			GB 1986-4422	19860221
			GB 1986-4423	19860221
			GB 1986-4424	19860221
			GB 1986-5000	19860228
			GB 1986-21514	19860906

$$R^4$$
  $F$   $CF_3$   $R^3O_2C$   $CO_2R^5$   $MeO_2C$   $CO_2CHMe_2$   $CHZXR^6$   $FH_2C$   $N$   $CH_2A$   $TI$ 

AB The title compds. I [R1 = H, alkyl; R2 = (fluoro)alkyl; R3 = alkyl; R4 = (un) substituted Ph, naphthyl, S-contg. heterocyclyl; R5 = (un) substituted alkyl, thietanyl; R6 = H, CH2CH2NH2, N-contg. heterocyclyl, etc.; X = O, NR, SOn, bond; Z = H; ZR = bond; n = 0-2] were prepd. as calcium channel blockers (no data). Title compd. II (A = H) was stirred with pyridinium bromide perbromide in CH2Cl2 contg. pyridine to give II (A = Br) which was stirred with NaOMe and pyridin-3-ol in MeCN to give II (A = 3-pyridyloxy).

IT112641-34-6P 112641-35-7P 112641-36-8P 112641-37-9P 112641-38-0P 112641-39-1P

112641-40-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction of, in prepn. of calcium channel blockers)

RN112641-34-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2yl)ethoxy]methyl]-6-(fluoromethyl)-1,4-dihydro-4-(5-nitro-2-thienyl)-,3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 112641-35-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(5-cyano-2-thienyl)-6-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]methyl]-2-(fluoromethyl)-1,2,3,4-tetrahydro-2-hydroxy-, 5-ethyl 2-methyl ester (9CI) (CA INDEX NAME)

RN 112641-36-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]methyl]-4-[3-(1,3-dioxolan-2-yl)-2-thienyl]-6-(fluoromethyl)-1,4-dihydro-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 112641-37-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]methyl]-6-(fluoromethyl)-4-(3-formyl-2-thienyl)-1,4-dihydro-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 112641-38-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]methyl]-6-(fluoromethyl)-1,4-dihydro-4-[3-[(hydroxyimino)methyl]-2-thienyl]-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 112641-39-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(3-cyano-2-thienyl)-2-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]methyl]-6-(fluoromethyl)-1,4-dihydro-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 112641-40-4 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]methyl]-6-(fluoromethyl)-1,4-dihydro-4-(3-methyl-2-thienyl)-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

IT 112640-36-5P 112640-37-6P 112640-38-7P 112640-39-8P 112640-97-8P 112692-77-0P 112692-78-1P 112692-79-2P 112692-80-5P 112693-00-2P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as calcium channel blocker)

RN 112640-36-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-6-(fluoromethyl)-1,4-dihydro-4-(5-nitro-2-thienyl)-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

$$H_2N-CH_2-CH_2-O-CH_2$$
 $H$ 
 $CH_2F$ 
 $C-OMe$ 
 $O_2N$ 

RN 112640-37-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(5-cyano-2-thienyl)-6-(fluoromethyl)-1,4-dihydro-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 112640-38-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(3-cyano-2-thienyl)-6-(fluoromethyl)-1,4-dihydro-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 112640-39-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-6-(fluoromethyl)-1,4-dihydro-4-(3-methyl-2-thienyl)-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 112640-97-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[2-[(5-amino-1H-1,2,4-triazol-3-yl)amino]ethoxy]methyl]-4-(3-cyano-2-thienyl)-6-(fluoromethyl)-1,4-dihydro-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 112692-77-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-6-(fluoromethyl)-1,4-dihydro-4-(5-nitro-2-thienyl)-, 3-ethyl 5-methyl ester, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 112640-36-5

CMF C18 H22 F N3 O7 S

CM 2

CRN 144-62-7 CMF C2 H2 O4

RN 112692-78-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(5-cyano-2-thienyl)-6-(fluoromethyl)-1,4-dihydro-, 3-ethyl 5-methyl ester, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 112640-37-6 CMF C19 H22 F N3 O5 S

$$H_2N-CH_2-CH_2-O-CH_2$$
 $H_2N-CH_2-CH_2-O-CH_2$ 
 $H_3$ 
 $CH_2F$ 
 $C-OMe$ 
 $O$ 
 $O$ 
 $O$ 

CM 2

CRN 144-62-7 CMF C2 H2 O4

RN 112692-79-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(3-cyano-2-thienyl)-6-(fluoromethyl)-1,4-dihydro-, 3-ethyl 5-methyl ester, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 112640-38-7 CMF C19 H22 F N3 O5 S

CM 2

CRN 144-62-7 CMF C2 H2 O4

RN 112692-80-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-6-(fluoromethyl)-1,4-dihydro-4-(3-methyl-2-thienyl)-, 3-ethyl 5-methyl ester, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 112640-39-8 CMF C19 H25 F N2 O5 S

CM 2

CRN 144-62-7

CMF C2 H2 O4

RN 112693-00-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[2-[(5-amino-1H-1,2,4-triazol-3-yl)amino]ethoxy]methyl]-4-(3-cyano-2-thienyl)-6-(fluoromethyl)-1,4-dihydro-, 3-ethyl 5-methyl ester, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 112640-97-8

CMF C21 H24 F N7 O5 S

NC 
$$S$$
  $O$   $O$   $NH_2$   $MeO-C$   $C-OEt$   $H$   $NH_2$   $C-OEt$   $NH_2$   $NH_2$ 

CM 2

CRN 144-62-7 CMF C2 H2 O4

L11 ANSWER 25 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1987:575780 CAPLUS

DOCUMENT NUMBER:

107:175780

TITLE:

Preparation of pyridinylflavone derivatives as calcium

antagonists and smooth muscle relaxants

INVENTOR(S):

Leonardi, Amedeo; Pennini, Renzo; Cazzulani, Pietro;

Nardi, Dante

PATENT ASSIGNEE(S):

Recordati S. A. Chemical and Pharmaceutical Co.,

Switz.

SOURCE:

Eur. Pat. Appl., 32 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO. DATE

EP 223744	A2	19870527		EP 1986-830300	19861020
EP 223744	A3	19880914			
EP 223744	B1	19920311			
R: AT,	BE, CH, DE	, ES, FR,	GB, GI	R, LI, LU, NL, SE	
IL 80229	A1	19901105		IL 1986-80229	19861003
NO 8604108	А	19870423		NO 1986-4108	19861015
NO 167570	В	19910812			
NO 167570	С	19911120			
ZA 8607941	А	19870624		ZA 1986-7941	19861020
ES 2002425	Аб	19880801		ES 1986-2677	19861020
AT 73453	E	19920315		AT 1986-830300	19861020
FI 8604260	A	19870423		FI 1986-4260	19861021
FI 89167	В	19930514			
FI 89167	С	19930825			
JP 62161781	A2	19870717		JP 1986-251553	19861021
JP 07072186	В4	19950802			
HU 45525	A2	19880728		HU 1986-4363	19861021
HU 202863	В	19910429			
CA 1330994	A1	19940726		CA 1986-520953	19861021
DK 8605063	А	19870423		DK 1986-5063	19861022
DK 169408	B1	19941024			
AU 8664273	A1	19870430		AU 1986-64273	19861022
AU 596382	В2	19900503			
CN 86107544	A	19871125		CN 1986-107544	19861022
US 4806534	A	19890221		US 1986-921397	19861022
PRIORITY APPLN. 1	NFO.:		IT	1985-22578	19851022
			EP	1986-830300	19861020
GI					

$$\begin{array}{c|c} & & & & \\ & & & & \\ & & & & \\ R^2O_2C & & & \\ & & & \\ R & & & \\ & & & \\ R & & \\ & & & \\ & & & \\ R^1 & & \\ \end{array}$$

I

AB Title compds. I (R, R1 = C1-4 alkyl, formylalkyl, cyanoalkyl, C1-4 hydroxyalkyl; R2, R3 = C1-6 alkyl, C2-6 alkenyl, -alkynyl, C5-7 cycloalkyl, aralkyl, Ph, etc., R4R5N-alkyl; R4, R5 = H, alkyl, Ph, etc., or R4R5N = heterocyclyl) their optical isomers, diastereomers, and salts were prepd. as calcium antagonists and smooth muscle relaxants.

3-Methyl-8-formylflavone, MeCOCH2CO2Me, MeC(NH2):CHCO2Me and EtOH were refluxed to give I (R-R3 = Me) (II). II had IC50 of 5.55 x 10-9 nM on Ca-antagonistic binding sites using rat brain membranes. in vitro. The activity on urodynamic parameters was detected by cystometric recordings on rats given II at 10 mg/kg orally; the changes in bladder vol. capacity and micturition pressure were +18 and -14%, resp.

T 110714-89-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and hydrolysis of)

110714-89-1 CAPLUS RN

CN 3,5-Pyridinedicarboxylic acid, 2-(dimethoxymethyl)-1,4-dihydro-6-methyl-4-(3-methyl-4-oxo-2-phenyl-4H-1-benzopyran-8-yl)-, dimethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 26 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1987:213771 CAPLUS

DOCUMENT NUMBER:

106:213771

TITLE:

Preparation of dihydropyridinedicarboxylates as

cardiovascular agents

INVENTOR(S):

Schwenner, Eckhard; Kinast, Guenther; Knorr, Andreas;

Kazda, Stanislav

PATENT ASSIGNEE(S):

Bayer A.-G. , Fed. Rep. Ger. Ger. Offen., 21 pp.

SOURCE:

CODEN: GWXXBX

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3531400		10070005		
DE 3531498	A1.	19870305	DE 1985-3531498	19850904
EP 218068	A1	19870415	EP 1986-111731	19860825
R: AT,	BE, CH, DE,	FR, GB, IT,	LI, NL, SE	
AU 8662160	A1	19870305	AU 1986-62160	19860902
FI 8603537	A	19870305	FI 1986-3537	19860902
JP 62056474	A2	19870312	JP 1986-205235	19860902
DK 8604209	A	19870305	DK 1986-4209	19860903
ZA 8606683	A	19870527	ZA 1986-6683	19860903
ES 2001641	A6	19880601	ES 1986-1577	19860903
PRIORITY APPLN.	INFO.:	1	DE 1985-3531498	19850904
GI				

$$\begin{array}{c|c}
R & CO_2R^1 \\
\hline
R_2 & N & CH_2OANR^4CH_2CH (OH) CH_2OR^5
\end{array}$$

The title compds. [I; R = (un) substituted aryl, N-heteroaryl; R1 = (un) substituted hydrocarbyl, cyclic hydrocarbyl, optionally with O or S interrupters; R2 = H, aryl, aralkyl, cyano, (un) substituted alkyl; R3 = H, alkyl, oxaalkyl, aryl, aralkyl; R4 = H, alkyl, aryl, acyl, R5CH2CH(OH)CH2; R5 = (un) substituted aryl, heteroaryl; A = (un) substituted C1-20 alkylene, cycloalkylene, optionally with phenylene or heteroatom interrupters; X = R10, (un) substituted alkyl, aryl, aralkyl, amino, heterocyclyl, PhNH] were prepd. as cardiovascular agents (no data). 3-Et 5-Me 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate and [(1-naphthyloxy)methyl]oxirane were refluxed 24 h in Me2CHOH to give 73.1% I (R = 2-ClC6H4, R1 = Et, R2 = Me, R3 = R4 = H, R5 = 1-naphthyl).

IT 108256-02-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of, as cardiovascular agent)

RN 108256-02-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-1,4-dihydro-2[[2-[[2-hydroxy-3-(1-naphthalenyloxy)propyl]amino]ethoxy]methyl]-6-methyl, 3-ethyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

L11 ANSWER 27 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1986:572250 CAPLUS

DOCUMENT NUMBER:

105:172250

TITLE:

Long-acting dihydropyridine calcium antagonists. 1. 2-Alkoxymethyl derivatives incorporating basic

substituents

AUTHOR(S):

Arrowsmith, John E.; Campbell, Simon F.; Cross, Peter

E.; Stubbs, John K.; Burges, Roger A.; Gardiner,

Donald G.; Blackburn, Kenneth J.

CORPORATE SOURCE:

SOURCE:

Pfizer Cent. Res., Sandwich/Kent, CT13 9NJ, UK Journal of Medicinal Chemistry (1986), 29(9), 1696-702

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE:

Journal

LANGUAGE:

English

OTHER SOURCE(S):

CASREACT 105:172250

GΙ

$$\begin{array}{c|c} \text{MeO}_2\text{C} & \\ \hline & \\ \text{Me} & \\ \text{N} & \\ \text{H} & \\ \text{CH}_2\text{O}\,\text{(CH}_2)\,\text{nR}^1 \end{array}$$

Aminoalkoxymethyldihydropyridines I [R = Ph, substituted Ph, 1-naphthyl, 2-thienyl, 4-pyridyl; R1 = (un)substituted NH2; n = 2, 3] were prepd. from RCHO, R1(CH2)nOCH2COCH2CO2Et, and H2NCMe:CHCO2Me or via I (R = N3, phthalimido). Their potencies as Ca antagonists were detd. I (R = 2-ClC6H4, R1 = NH2, n = 2) (amlodipine) was comparable in potency to nifedipine and had an elimination half-life of 30 h in dogs. Oral bioavailability approached 100%, and hemodynamic responses were gradual in onset and long-lasting in effect. The two enantiomers were prepd.; the bulk of the activity resided with the (-)-isomer. X-ray crystallog. studies, carried out on I (R = 2-ClC6H4, R = morpholinosulfonyl, n = 2) suggest the existence of a weak H bond between the side-chain O and the H on the ring N.

IT 84157-48-2P 103069-24-5P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and calcium antagonist activity of)

RN 84157-48-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[2-(dimethylamino)ethoxy]methyl]-1,4-dihydro-6-methyl-4-(2-thienyl)-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN 103069-24-5 CAPLUS

CN [4,4'-Bipyridine]-3,5-dicarboxylic acid, 2-[[2-(dimethylamino)ethoxy]methyl]-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c} \text{O} \\ \parallel \\ \text{C-OMe} \\ \text{Me} \\ \text{HN} \\ \text{C-OEt} \\ \parallel \\ \text{Me}_2\text{N-CH}_2\text{-CH}_2\text{-O-CH}_2 \\ \text{O} \end{array}$$

L11 ANSWER 28 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1986:442661 CAPLUS

DOCUMENT NUMBER:

105:42661

TITLE:

2-(Secondary aminoalkoxymethyl)dihydropyridine derivatives as anti-ischemic and antihypertensive

agents

INVENTOR(S):

Campbell, Simon F.; Cross, Peter E.; Stubbs, John K.

Pfizer Inc., USA

PATENT ASSIGNEE(S): SOURCE:

U.S., 15 pp. Cont.-in-part of U.S. Ser. No. 463,081,

abandoned.

CODEN: USXXAM

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
		<del>-</del>		
US 4572909	A	19860225	US 1984-576982	19840203
CS 240998	B2	19860313	CS 1984-1592	19840406
NO 8604435	Α	19830912	NO 1986-4435	19861106
NO 170275	В	19920622		
NO 170275	С	19920930		
PRIORITY APPLN. INFO.	:	(	GB 1982-7180	19820311
		τ	JS 1983-463081	19830202
		(	CS 1983-1499	19830303
		1	NO 1983-847	19830708

GΙ

AΒ Dihydropyridines I [Y = (CH2)2, (CH2)3, CH2CHMe, CH2CMe2; R = (un) substituted aryl; R1, R2 = alkyl, MeOCH2CH2; R3 = H, alkyl, 2-alkoxyethyl, cyclopropylmethyl, PhCH2, (CH2)mCOR4; m = 1-3; R4 = OH, alkoxy, NR5R6; R5,R6 = H, alkyl] and their pharmaceutically acceptable acid addn. salts, useful as antiischemic and antihypertensive agents, were prepd. PhCH2NMeCH2CH2OH reacted with ClCH2COCH2CO2Et and NaH in THF to

give PhCH2NMeCH2CH2COCH2COCH2CO2Et which reacted with 2-ClC6H4CHO, H2NCMe:CHCO2Me, and AcOH in MeOH to give dihydropyridine II (R7 = CH2Ph). Hydrogenolysis of this gave II (R7 = H), characterized as the oxalate (III). III had IC50 (IC = inhibitory concn.) 3.2 .times. 10-9M for in vitro Ca uptake by isolated heart tissue.

IT 103198-59-0P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as antiischemic or antihypertensive)

RN 103198-59-0 CAPLUS

CN [3,4'-Bipyridine]-3',5'-dicarboxylic acid, 2'-[(2-aminoethoxy)methyl]-2-chloro-1',4'-dihydro-6'-methyl-, 3'-ethyl 5'-methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ \text{MeO-C} & & \\ & & & \\ & & & \\ & &$$

IT 103198-45-4P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as intermediate for dihydropyridine pharmaceuticals)

RN 103198-45-4 CAPLUS

CN [3,4'-Bipyridine]-3',5'-dicarboxylic acid, 2-chloro-2'-[[2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)ethoxy]methyl]-1',4'-dihydro-6'-methyl-, 3'-ethyl 5'-methyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 29 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1986:424274 CAPLUS

DOCUMENT NUMBER:

105:24274

TITLE:

Dihydropyridinedicarboxylate cardiovascular agents

INVENTOR(S):

Arrowsmith, John Edmund; Cross, Peter Edward; Campbell, Simon Fraser; Dickinson, Roger Peter

PATENT ASSIGNEE(S):

Pfizer Ltd., UK; Pfizer Corp.

SOURCE:

Eur. Pat. Appl., 51 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

т∙ 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 168151	A1	19860115	EP 1985-303788	19850530
R: AT, BE,	CH, DE	, FR, GB,	IT, LI, LU, NL, SE	
FI 8502221	A	19851208	FI 1985-2221	19850603
US 4647565	A	19870303	US 1985-741416	19850605
DK 8502535	Α	19851208	DK 1985-2535	19850606
AU 8543347	A1	19851212	AU 1985-43347	19850606
AU 554571	В2	19860828		
JP 61033185	A2	19860217	JP 1985-123484	19850606
ни 37933	A2	19860328	HU 1984-2248	19850606
ES 543997	A1	19870401	ES 1985-543997	19850607
PRIORITY APPLN. INFO	o.:		GB 1984-14518	19840607

$$R^{10}2C$$
 $R^{10}2C$ 
 $R^{10}2C$ 

AB 2-(Heteroaryl aminoalkoxymethyl)dihydropyridinedicarboxylates I [R = aryl, heteroaryl; R1,R2 = alkyl, HOCH2CH2, MeOCH2CH2; R3,R4 = H, alkyl; R3R4 N = heterocyclyl; R5 = (hydroxy)alkyl, alkoxyalkyl; R6 = alkyl, alkoxy, halo, CF3; X = CH, N; Z = alkylene; ZNR5 may form a ring; n = 0-3] were prepd. as cardiotonics and antihypertensives (no data). Thus, 2-BrC6H4CHO was cyclocondensed with Me2NCH2CH2OCH2COCH2CO2Et and H2NCH2CH:CHCO2Me to give dihydropyridinedicarboxylate II (R7 = Me). This was treated with Cl3CCH2O2CCl and then Zn dust to give II (R7 = H). The latter was condensed with 4-amino-2-chloro-6,7-dimethoxyquinazoline to give II (R7 = Q).

#### IT 102672-11-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and cyanation of)

RN 102672-11-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2-chloro-3-thienyl)-2-[[2-(dimethylamino)ethoxy]methyl]-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

IT 102672-12-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and cyclocondensation of, with aminobenzonitriles)

RN 102672-12-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2-chloro-3-thienyl)-2-[[2-(cyanomethylamino)ethoxy]methyl]-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} CN \\ Me-N-CH_2-CH_2-O-CH_2 & H \\ EtO-C & C-OMe \\ \hline \\ O & O \\ \end{array}$$

IT 102671-97-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of as cardiotonic and antihypertensive)

RN 102671-97-6 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[2-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]ethoxy]methyl]-4-(2-chloro-3-thienyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 30 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1986:148754 CAPLUS

DOCUMENT NUMBER: 104:148754

TITLE: Dihydropyridines

INVENTOR(S): Alker, David; Campbell, Simon Fraser; Cross, Peter

Edward

PATENT ASSIGNEE(S): Pfizer Ltd., UK; Pfizer Corp.

SOURCE: Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

						APPLICATION NO.	DATE
ΕP	161917		A2	19851121		EP 1985-303304	19850510
ΕP	161917		A3	19871202 19900314			
ΕP	161917		B1	19900314			
						LI, LU, NL, SE	
US	4654353		A	19870331		US 1985-727704	19850426
JP	60246368		A2	19851206		JP 1985-98876	19850509
JР	05029029		B4	19930428			
FI	8501857		Α	19851113		FI 1985-1857	19850510
FI	83308		В	19910315 19910625			
FI	83308		С	19910625			
NO	8501886		Α	19851113		NO 1985-1886	19850510
DK	8502078		Α	19851113		DK 1985-2078	
DK	162982		В	19920106 19920601			
DK	162982		С	19920601			
ΑU	8542269		A1	19851114		AU 1985-42269	19850510
AU	554257		В2	19860814			
						ни 1985-1778	19850510
				19880128			
	235867			19860521		DD 1985-276212	
ES	543033		A1	19860901		ES 1985-543033	19850510
	8503543					ZA 1985-3543	19850510
IL	75165		A1	19880930		IL 1985-75165	
	50988					AT 1985-303304	
						CA 1985-481320	
						SU 1985-3901005	
ES	550965		A1	19870216		ES 1986-550965	19860116
₹IΤ?	Y APPLN.	INFO	.:			GB 1984-12208	
					]	EP 1985-303304	19850510

PRIO

GΙ

AB The title compds. I (R = aryl, heterocyclyl; R1, R2 = C1-4 alkyl, MeOCH2CH2; Y = (CH2)n, CH2CHMe, CH2CMe2; n = 2-4) and their salts, useful as antiischemic and antihypertensive agents (no data), were prepd. Thus, 2-[[4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl]methoxy]acetic acid was reduced with borane in THF to

give I (R = 2-C1C6H4, R1 = Me, R2 = Et, Y = CH2CH2).

IT 101465-94-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and redn. of)

RN 101465-94-5 CAPLUS

CN [3,4'-Bipyridine]-3',5'-dicarboxylic acid, 2'-[(carboxymethoxy)methyl]-2-chloro-1',4'-dihydro-6'-methyl-, 3'-ethyl 5'-methyl ester (9CI) (CA INDEX NAME)

IT 101411-56-7P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as antiischemic and antihypertensive agent)

RN 101411-56-7 CAPLUS

CN [3,4'-Bipyridine]-3',5'-dicarboxylic acid, 2-chloro-1',4'-dihydro-2'-[(2-hydroxyethoxy)methyl]-6'-methyl-, 3'-ethyl 5'-methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} N \\ \text{C1} \\ \text{O} \\ \text{O} \\ \text{MeO-C} \\ \text{C} \\ \text{C}$$

L11 ANSWER 31 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1985:606480 CAPLUS

DOCUMENT NUMBER:

103:206480

TITLE:

Biological activity of 1,4-dihydropyridine derivatives

AUTHOR(S): Fiszer-Maliszewska, Lucja; Wieczorek, Jadwiga;

Mordarski, Marian; Balicki, Roman; Kaczmarek, Lukasz;

Nantka-Namirski, Pawel

CORPORATE SOURCE:

Inst. Immunol. Exp. Ther., Pol. Acad. Sci., Wroclaw,

53-114, Pol.

SOURCE:

Archivum Immunologiae et Therapiae Experimentalis

(1985), 33(219), 345-52

CODEN: AITEAT; ISSN: 0004-069X

DOCUMENT TYPE:

Journal

LANGUAGE:

English

GΙ

Six new 1,4-dihydropyridine derivs. were evaluated in vitro for AΒ antimicrobial and cytotoxic effects and in vivo for antineoplastic activity. The compds. inhibited the growth of most of gram-pos. and gram-neg. bacteria at concns. of 50 and 100 .mu.g/mL. Concns. effective against fungi were somewhat lower (25-50 .mu.g/mL). The growth of mycobacteria was inhibited at concns. of 3.1-25 .mu.g/mL. Compd. I [71569-90-9] inhibited the growth of pathogenic mycobacteria including M. tuberculosis resistant to streptomycin and isonicotinate hydrazide at 3.1 or 6.2 .mu.g/mL. In cytotoxicity assays, compd. I, II [ **71569-81-8**], and III [99242-29-2] appeared the most active. However, none of the 1,4-dihydropyridine derivs. affected the survival time of mice with P388 and L1210 leukemias or melanoma B16. The growth of s.c. tumors of sarcoma 180 was inhibited by compds. I, III, IV [71569-91-0], and V [71569-82-9]. The effect was dose related.

IT 71569-81-8 71569-82-9

RL: BIOL (Biological study) (antibacterial and neoplasm-inhibiting activity of)

RN 71569-81-8 CAPLUS

[4,4'-Bipyridine]-2,3,5,6-tetracarboxylic acid, 1,4-dihydro-, tetraethyl CN ester (9CI) (CA INDEX NAME)

RN71569-82-9 CAPLUS

[3,4'-Bipyridine]-2',3',5',6'-tetracarboxylic acid, 1',4'-dihydro-, CN tetraethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 32 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1985:578176 CAPLUS

DOCUMENT NUMBER:

103:178176

TITLE:

Halogenated thiophene compounds

INVENTOR(S):

Kuehnis, Hans

PATENT ASSIGNEE(S):

Ciba-Geigy A.-G. , Switz.

SOURCE:

Ger. Offen., 54 pp. CODEN: GWXXBX

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
		<del>_</del>		
DE 3445356	A1	19850627	DE 1984-3445356	19841212
PRIORITY APPLN. INFO	).:		СН 1983-6692	19831215
GI				

III

$$R^4$$
 $R^5$ 
 $R^5$ 
 $R^5$ 
 $R^6$ 
 $R^7$ 
 $R^8$ 
 $R^8$ 

CO<sub>2</sub>Me

Me

Thienylpyridines I [R = halothienyl; R1 = H, (un)substituted alkyl; 1 of R2 and R3 = alkyl, the other = H, amino, (un)modified CO2H, (un)substituted alkyl; R1R2, R1R3 = azaalkylene; R4, R5 = acyl, e.g., alkanoyl, (un)modified CO2H, (un)substituted PhCO, PhSO2] were prepd. Thus, 3,4-dichloro-2-thiophenecarboxaldehyde was condensed with MeCOCH2CO2Me to give (thienylmethylene)acetoacetate II. This was cyclocondensed with H2NCMe:CHCO2Me to give thienylpyridinedicarboxylate III. I are antihypertensives, reducing blood pressure in cats by 94 mm Hg with a single dose of 1 mg/kg i.v., the effect lasting 6 h.

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and acid hydrolysis of)

RN 98770-45-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(3,4-dichloro-2-thienyl)-2-(diethoxymethyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 33 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1985:203874 CAPLUS

DOCUMENT NUMBER:

102:203874

TITLE:

Pharmaceutically active dihydropyridines

INVENTOR(S):

Baxter, Andrew John Gilby; Dixon, John; Gould, Kenneth

John; McInally, Thomas; Tinker, Alan Charles

PATENT ASSIGNEE(S):

SOURCE:

Fisons PLC, UK

Eur. Pat. Appl., 111 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

LANGUAGE:

Patent English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA'	TENT NO.		KIND	DATE		DATE
				19841121 19870121	EP 1984-302566	19840416
					IT, LI, LU, NL, SE	
US	4607041	,, -			US 1984-601389	19840417
US	4686217				US 1984-601309	19840417
FI	8401597				FI 1984-1597	19840424
ZA	8403030		Α	19850227	ZA 1984-3030	19840424
DK	8402092		A	19841028	DK 1984-2092	19840426
ИО	8401656		A	19841029	NO 1984-1656	19840426
JP	5920536	0 .	A2	19841120		19840426
ES	531940		A1	19861201	ES 1984-531940	19840426
AU	8427445		A1	19841101		19840427
DD	232491		A5	19860129	DD 1984-266853	19840831
HU	36093		A2	19850828	HU 1984-3693	19840928
PRIORIT	Y APPLN.	INFO.:			GB 1983-11519	19830427
					GB 1983-11520	19830427
					GB 1983-11521	19830427
					GB 1983-26362	19831001
					GB 1983-27660	19831015

GB	1983-27661	19831015
GB	1983-30852	19831118
GB	1983-34285	19831222
GB	1983-34286	19831222
GB	1983-34287	19831222

GΙ

$$R^{3}O_{2}C$$
 $R^{4}$ 
 $CO_{2}R^{2}$ 
 $R^{1}$ 
 $Me_{2}CHO_{2}C$ 
 $CO_{2}Me$ 
 $R^{5}$ 
 $R^{6}$ 
 $R^{6$ 

AB Calcium channel-blocking (no data) di- and tetrahydropyridinedicarboxylate s I [R = OH, R1 = H; RR1 = bond; R2, R3 = H, (un)substituted alkyl, cycloalkyl, heterocyclyl; R1 = benzofurazanyl, (un)substituted alkyl, Ph, pyridyl, R5, R6 = alkyl, C(X)R1, S(O)nR8, (un)substituted Ph; R1 = amino, alkylthio; R8 = alkyl; X = O, S; n = O-2] (125 compds.) were prepd. Thus, FCH2COCH2CO2Me, prepd. by condensing FCH2COCl with 2,2-dimethyl-1,3-dioxane-4,6-dione followed by methanolysis, was stirred at 90.degree. with 2,3-Cl2C3H3CHO and H2NCMe:CHCO2CHMe2 to give II.

## IT 95400-34-3P 95410-44-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 95400-34-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2-(diethoxymethyl)-1,4-dihydro-6-(trifluoromethyl)-, diethyl ester (9CI) (CA INDEX NAME)

RN 95410-44-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-6-(diethoxymethyl)-1,2,3,4-tetrahydro-2-hydroxy-2-(trifluoromethyl)-, diethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 34 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1985:24483 CAPLUS

DOCUMENT NUMBER:

102:24483

TITLE:

Dihydropyridines

INVENTOR(S):

Campbell, Simon Fraser; Cross, Peter Edward; Stubbs,

John Kendrick

PATENT ASSIGNEE(S):

Pfizer Ltd., UK; Pfizer Corp.

SOURCE:

Eur. Pat. Appl., 72 pp. CODEN: EPXXDW

Patent

DOCUMENT TYPE: LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE		APPLICATION NO.	DATE
EP 106462	A2	19840425		EP 1983-304954	19830826
EP 106462	A3	19840530			
EP 106462	B1	19881207			
· ·	•		-	, LU, NL, SE	1000000
AT 39112	E	19881215		AT 1983-304954	
ES 525241	A1	19860116		ES 1983-525241	•
FI 8303117	А	19840305		FI 1983-3117	19830901
FI 80262	В	19900131			
FI 80262	С	19900510			
DK 8303983	А	19840305		DK 1983-3983	19830901
DK 161700	В	19910805	•		
DK 161700	С	19920106			
US 4539322	Α	19850903		US 1983-528507	19830901
NO 8303159	Α	19840305		NO 1983-3159	19830902
NO 160259	В	19881219			
NO 160259	С	19890329			
AU 8318658	A1	19840308		AU 1983-18658	19830902
AU 542454	B2	19850221			
HU 31719	0	19840528		HU 1983-3077	19830902
HU 191092	В	19870128			
ZA 8306514	A	19840725		ZA 1983-6514	19830902
DD 215544	A5	19841114	•	DD 1983-254486	19830902
CS 242881	В2	19860515		CS 1983-6395	19830902
CA 1205470	A1	19860603		CA 1983-435935	19830902
IL 69627	A1	19860831		IL 1983-69627	19830902
PL 139499	В1	19870131		PL 1983-243621	19830902
SU 1364237	A3	19871230		SU 1983-3641411	19830902
PL 143900	В1	19880331		PL 1983-250618	19830902

JP 59080663	A2	19840510		JP 1983-163103	19830905
JP 62022985	B4	19870520			
ES 532038	<b>A</b> 1	19851201		ES 1984-532038	19840430
SU 1378782	A3	19880228		SU 1984-3750492	19840611
CS 242898	B2	19860515		CS 1984-7706	19841010
PRIORITY APPLN. INFO.:			GB	1982-25246	19820904
			US	1983-463092	19830202
			ΕP	1983-304954	19830826
			CS	1983-6395	19830902

GΙ

AB 1,4-Dihydropyridines I [R = aryl, heteroaryl; R1 and R2 are alkyl, CH2CH2OMe; Z = CH2CH2, (CH2)3, CH2CHMe, CH2CMe2; R3 = H, a carbamoyl, thiocarbamoyl, guanyl, or imino (methylthio) methyl group] were prepd. and they showed anti-ischemic activity. Thus, I [R = 2-ClC6H4, R1 = Me, R2 = Et, Z = CH2CH2, R3 = C(:NCN) SMe] was treated with MeNH2 to give I [R = 2-ClC6H4, R1 = Me, R2 = Et, Z = CH2CH2, R3 = C(:NCN) NHMe]. In tests with rat aorta tissue I reduced the response to increased Ca2+ concn. with IC50 values as low as 2 x 10-9 M.

### IT 92601-04-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and anti-ischemic activity of)

RN 92601-04-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2-methyl-6-[[2-[4-[(methylamino)carbonyl]-1-piperazinyl]ethoxy]methyl]-4-(2-thiazolyl)-, 5-ethyl 3-methyl ester (9CI) (CA INDEX NAME)

### IT 92600-99-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and N-carbamoylation of)

RN 92600-99-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2-methyl-6-[[2-(1-piperazinyl)ethoxy]methyl]-4-(2-thiazolyl)-, 5-ethyl 3-methyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 35 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1984:51576 CAPLUS

DOCUMENT NUMBER:

100:51576

TITLE:

1,4-Dihydropyridine derivatives and pharmaceutical

preparations containing them

INVENTOR(S):

Vogel, Arnold

PATENT ASSIGNEE(S):

Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.

SOURCE:

Ger. Offen., 32 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

Patent German

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PA'	TENT NO.	KIND	DATE		APPLICATION NO.	DATE
DE	3305577	A1	19830922		DE 1983-3305577	19830218
ZA	8300959	A	19840926		ZA 1983-959	19830211
DK	8300635	A	19830911		DK 1983-635	19830214
BE	895957	<b>A</b> 1	19830822		BE 1983-10727	19830221
AU	8311695	A1	19830915		AU 1983-11695	19830221
FR	2523128	<b>A</b> 1	19830916		FR 1983-2895	19830221
FR	2523128	В1	19851018			
FI	8300617	Α	19830911		FI 1983-617	19830224
WO	8303097	A1	19830915		WO 1983-CH20	19830224
	W: CH					
CH	660190	A	19870331		CH 1983-6050	19830224
SE	8301072	Α	19830911		SE 1983-1072	19830225
NL	8300739	Α	19831003		NL 1983-739	19830228
GB	2117761	<b>A</b> 1	19831019		GB 1983-5525	19830228
GB	2117761	В2	19860129			
JP	58180483	A2	19831021		JP 1983-32694	19830228
HU	31191	0	19840428		HU 1983-671	19830228
ES	520201	A1	19841001		ES 1983-520201	19830301
PRIORIT	Y APPLN. INFO.:			CH	1982-1477	19820310
				WO	1983-CH20	19830224

GΙ

Calcium channel-blocking (no data) I [R, R1 = esterified carboxy; R2 = H, alkyl, cyano; R3 = (un)substituted alkyl, alkenyl, cycloalkyl, phenylalkyl, phenylalkenyl; R4 = (un)substituted benzothiadiazolyl, benzoxadiazolyl] were prepd. Thus, iso-Pr 2-acetyl-3-(2,1,3-benzoxadiazol-4-yl)-2-propenoate was cyclocondensed with (MeO)2CHC(NH2):CHCO2Me to give II [R5 = (MeO)2CH, R6 = H]. This was hydrolyzed to give II (R5 = CHO, R6 = H), oximated, dehydrated, and methylated to give (.+-.)-II (R5 = cyano, R6 = Me).

IT 88123-83-5P 88123-87-9P 88123-88-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and deacetalization of)

RN 88123-83-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2-(dimethoxymethyl)-1,4-dihydro-6-methyl-, 3-methyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 88123-87-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2-(dimethoxymethyl)-1,4-dihydro-6-methyl-, 3-methyl 5-(1-methylethyl) ester, (-)- (9CI) (CA INDEX NAME)

Rotation (-).

RN 88123-88-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2-(dimethoxymethyl)-1,4-dihydro-6-methyl-, 3-methyl 5-(1-methylethyl) ester, (+)- (9CI) (CA INDEX NAME)

Rotation (+).

# IT 88123-86-8P 88152-96-9P

RN 88123-86-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2-(dimethoxymethyl)-1,4-dihydro-6-methyl-, 3-(2-methoxy-2-phenylethyl) 5-(1-methylethyl) ester, [R-(R\*,S\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 88152-96-9 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2-(dimethoxymethyl)-1,4-dihydro-6-methyl-, 3-(2-methoxy-2-phenylethyl) 5-(1-methylethyl) ester, [R-(R\*,R\*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L11 ANSWER 36 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1983:575596 CAPLUS

DOCUMENT NUMBER:

99:175596

TITLE: INVENTOR(S):

Dihydropyridines and their use as pharmaceuticals

Dixon, John; Tinker, Alan Charles

PATENT ASSIGNEE(S):

Fisons PLC, UK

SOURCE:

Eur. Pat. Appl., 36 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 80220	A1	19830601	EP 1982-201367	19821101
EP 80220	B1	19860219		
R: AT,	BE, CH, DE	, FR, GB, IT	, LI, LU, NL, SE	
AT 18046	E	19860315	AT 1982-201367	19821101
FI 8203883	A	19830518	FI 1982-3883	19821112

DK 8205054	Α	19830518	DK 1982-5054	19821112
NO 8203829	Α	19830518	NO 1982-3829	19821116
AU 8290630	A1	19830526	AU 1982-90630	19821116
AU 551941	В2	19860515		
JP 58092679	A2	19830602	JP 1982-199876	19821116
PRIORITY APPLN. INFO.:			GB 1981-34550	19811117
			GB 1982-24923	19820901
			EP 1982-201367	19821101
a =				

GΙ

$$R^{1}O_{2}C$$
 $CO_{2}R^{2}$ 
 $R^{3}$ 
 $CH=C(CO_{2}Et)COCH(OEt)_{2}$  II

AB Pyridine derivs. I [Z = O, S; R = alkyl; R1 and R2 (same or different) are alkyl, an N,N-disubstituted .omega.-aminoalkyl group, (CH2)nOR4 (n = 2, 3, 4; R4 = alkyl, Ph); R3 = CH2OH, cyano, dialkoxymethyl, CHO, CH:NOH, CF3, or R3 and CO2R2 form a lactol] were prepd. as cardiovascular agents (no data). Thus, 4-benzofurazancarboxaldehyde reacted with (EtO)2CHCOCH2CO2Et and piperidine in C6H6 at reflux, and the condensation product II was heated with MeC(NH2):CHCO2Et 16 h at 100.degree. to give I [Z = O, R = Me, R1 = R2 = Et, R3 = CH(OEt)2].

### IT 87516-26-5P 87516-29-8P 87516-30-1P

87516-37-8P 87522-76-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 87516-26-5 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2- (diethoxymethyl)-1,4-dihydro-6-methyl-, diethyl ester (9CI) (CA INDEX NAME)

RN 87516-29-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2-(dimethoxymethyl)-1,4-dihydro-6-methyl-, dimethyl ester (9CI) (CA INDEX NAME)

RN 87516-30-1 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2-(diethoxymethyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 87516-37-8 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzoxadiazol-4-yl)-2-[bis(1-methylethoxy)methyl]-1,4-dihydro-6-methyl-, 3-ethyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 87522-76-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-(2,1,3-benzothiadiazol-4-yl)-2- (diethoxymethyl)-1,4-dihydro-6-methyl-, diethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 37 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1983:539790 CAPLUS

DOCUMENT NUMBER:

99:139790

TITLE:

Pyridine N-oxides and pharmaceutical compositions

containing them

INVENTOR(S):

Zimmermann, Markus; Kuehnis, Hans

PATENT ASSIGNEE(S): SOURCE:

Ciba-Geigy A.-G. , Switz. Eur. Pat. Appl., 72 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
		<del>-</del>		
EP 83315	A2	19830706	EP 1982-810572	19821230
EP 83315	A3	19830824		
EP 83315	B1	19870729		
R: AT, BE,	CH, DE	, FR, IT, LI,	LU, NL, SE	
US 4497808	Α	19850205	US 1982-453393	19821227
JP 58126885	A2	19830728	JP 1982-235045	19821229
HU 30614	0	19840328	HU 1982-4229	19821229

HU	192760	В	19870728				
FT	8204531	A	19830701		тч	1982-4531	19821230
DK		A	19830701			1982-5802	19821230
NO	8204420	A	19830701		NO	1982-4420	19821230
AU	8291959	A1	19830707		AU	1982-91959	19821230
AU	556201	В2	19861023				
GB	2112782	A1	19830727		GB	1982-36958	19821230
GB	2112782	В2	19850501				
ZA	8209573	A	19831026		ZA	1982-9573	19821230
DD	209456	A5	19840509		DD	1982-246796	19821230
ES	518711	A1	19840616		ES	1982-518711	19821230
CA	1215053	A1	19861209		CA	1982-418753	19821230
AT	28643	E	19870815		ΑT	1982-810572	19821230
ES	530655	A1	19851201		ES	1984-530655	19840315
ES	530653	A1	19851216		ES	1984-530653	19840315
ES	530654	<b>A</b> 1	19861116		ES	1984-530654	19840315
PRIORITY	APPLN. INFO.:			CH	198	31-8359	19811230
				CH	198	32-2255	19820414
				EΡ	198	32-810572	19821230

GΙ

$$\mathbb{Q}^1$$
 $\mathbb{Q}^2$ 
 $\mathbb$ 

AB I [R = (un)substituted 1-oxidopyridyl; R1 = H or (un)substituted lower alkyl; one of R2, R3 = lower alkyl, the other = H, lower alkyl, OH or deriv., CO2H or deriv., etc.; Q1 and Q2 = acyl, or an R and a Q group form a 1-oxa-2-oxoalkylene] were prepd. as antihypertensives and coronary vasodilators (no data). Thus, 12.4 g 3-pyridinecarboxaldehyde 1-oxide, 17.3 mL MeCOCH2CO2Me, 16 mL abs. EtoH, and 8 mL 30% aq. NH3 were heated 2 h at 100.degree. to give II.

#### IT 87217-42-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of, as antihypertensive)

RN 87217-42-3 CAPLUS

CN [3,4'-Bipyridine]-3',5'-dicarboxylic acid, 1',4'-dihydro-2'- (methoxymethyl)-6'-methyl-, 5'-ethyl 3'-methyl ester, 1-oxide (9CI) (CA INDEX NAME)

L11 ANSWER 38 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1983:34509 CAPLUS

DOCUMENT NUMBER:

98:34509

TITLE:

Dihydropyridine antiischemic and antihypertensive agents and pharmaceutical compositions containing them Campbell, Simon Fraser; Cross, Peter Edward; Stubbs,

INVENTOR(S):

John Kendrick

PATENT ASSIGNEE(S):

Pfizer Ltd., UK; Pfizer Corp.

SOURCE:

Eur. Pat. Appl., 36 pp. CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PA!	TENT NO.	KIND	DATE		AP:	PLICATION NO.	DATE
ΕP	60674	A1	19820922		EP	1982-301210	19820309
EΡ	60674	B1	19850918				
			, FR, GB,	IT,	LU, 1	NL, SE	
CS	228917	P	19840514			1982-1571	19820308
HU	26716	0	19830928		HU	1982-722	19820309
HU	187657	В	19860228				
PL	131190	B1	19841031		PL	1982-235363	19820309
PL	132199	В1	19850228		PL	1982-238960	19820309
AT	15660	E	19851015		AT	1982-301210	19820309
FI	8200840	А	19820915		FI	1982-840	19820311
FI	78470	В	19890428				
FI	78470	С	19890810				
DD	202430	<b>A</b> 5	19830914		DD	1982-238073	19820311
US	4430333	Α	19840207		US	1982-357229	19820311
IL	65222	A1	19850830		IL	1982-65222	19820311
NO	8200825	Α	19820915		ИО	1982-825	19820312
NO	159085	В	19880822				
NO	159085	С	19881130				
DK	8201099	A	19820915		DK	1982-1099	19820312
DK	155601	В	19890424				
DK	155601	С	19890911				,
ΑU	8281364	<b>A</b> 1	19821104		AU	1982-81364	19820312
AU	529854	B2	19830623				
zA	8201670	Α	19830126		ZA	1982-1670	19820312
ES	510402	A1	19830401		ES	1982-510402	19820312
CA	1205480	A1	19860603		CA	1982-398201	19820312
JP	57206659	A2	19821218		JP	1982-40082	19820313
JΡ	61055907	B4	19861129				
SU	1189336	A3	19851030		SU	1982-3527222	19821214
ES	518489	A1	19840116		ES	1982-518489	19821222
CS	228943	P	19840514		CS	1983-125	19830107
RITY	APPLN. INFO.	:		G	B 198	31-8088	19810314
				E	EP 198	32-301210	19820309

$$R^{1}O_{2}C$$
 $CO_{2}R^{2}$ 
 $CH_{2}O(CH_{2})_{n}NR^{3}R^{4}$ 

Dihydropyridines I (R = aryl, heteroaryl; R1, R2 = alkyl, CH2CH2OMe; R3, R4 = alkyl, aralkyl; NR3R4 = pyrrolidino, piperidino, morpholino, 4-substituted piperazino; n = 2, 3) were prepd. Thus, ClCH2COCH2CO2Et was treated with Me2NCH2CH2OH to give Me2NCH2CH2OCH2COCH2CO2Et, which was treated with H2NCMe:CHCO2Et and 1-naphthaldehyde to give I (R = 1-naphthyl, R1 = R2 = Et, R3 = R4 = Me, n = 2).

IT 84157-35-7P 84157-47-1P 84157-48-2P 84157-49-3P 84157-50-6P

RN 84157-35-7 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[3-(dimethylamino)propoxy]methyl]-1,4-dihydro-6-methyl-4-(2-thienyl)-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} \text{Me}_2\text{N-} (\text{CH}_2)_3 - \text{O-} \text{CH}_2 & \text{H} & \text{Me} \\ \\ \text{EtO-} & \text{C} & \text{C-} \text{OMe} \\ \\ \text{O} & \text{S} & \text{O} \end{array}$$

RN 84157-47-1 CAPLUS

CN [3,4'-Bipyridine]-3',5'-dicarboxylic acid, 2'-[[2-(dimethylamino)ethoxy]methyl]-1',4'-dihydro-6'-methyl-, 3'-ethyl 5'-methyl ester (9CI) (CA INDEX NAME)

RN 84157-48-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-[[2-(dimethylamino)ethoxy]methyl]-1,4-dihydro-6-methyl-4-(2-thienyl)-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN84157-49-3 CAPLUS

3,5-Pyridinedicarboxylic acid, 4-(5-bromo-2-thienyl)-2-[[2-CN (dimethylamino)ethoxy]methyl]-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

RN84157-50-6 CAPLUS

CN3,5-Pyridinedicarboxylic acid, 2-[[2-(dimethylamino)ethoxy]methyl]-1,4dihydro-6-methyl-4-(4-quinolinyl)-, 3-ethyl 5-methyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 39 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1982:6590 CAPLUS

DOCUMENT NUMBER:

TITLE:

1,4-Dihydropyridine derivatives, and their

pharmaceutical use

INVENTOR(S):

Satu, Yoshinari

PATENT ASSIGNEE(S):

SOURCE:

Fujisawa Pharmaceutical Co., Ltd., UK U.S., 43 pp. Cont.-in-part of U.S. Ser. No. 809,788, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: LANGUAGE:

Patent

FAMILY ACC. NUM. COUNT: 5

English

PATENT NO.	KIND	DATE	A:	PPLICATION NO.	DATE
US 4284634	 А	19810818	U	s 1979-39752	19790517
GB 1552911	A	19790919	G1	3 1975-27945	19750702
BE 843576	A1	19761229	Β	E 1976-168458	19760629
US 4145432	Α	19790320	U:	s 1976-701994	19760701
CS 189011	P	19790330	C	5 1976-4356	19760701
CS 189047	P	19790330	C	s 1977-2596	19760701
CS 189048	P	19790330		5 1977-2597	19760701
CS 189049	P	19790330	C	S 1977-2598	19760701
CS 189050	P	19800229	C	s 1977-2599	19760701
NL 7607338	Α	19770104	N:	L 1976-7338	19760702
NL 190812	В	19940405			
NL 190812	С	19940901			
JP 52005777	A2	19770117	J	2 1976-79413	19760702
JP 59048827	B4	19841129			
ни 173063	P	19790228	H	J 1976-FU342	19760702
HU 173064	P	19790228	H	J 1976-FU350	19760702
ни 173195	P	19790328		J 1976-FU353	19760702
HU 173193	P	19790328	H	J 1976-FU351	19760702
HU 173194	P	19790328		J 1976-FU352	19760702
AT 7604856	Α	19800615	A.	Ր 1976-4856	19760702
AT 360531	В	19810112			
CA 1080223	Al	19800624	C2	A 1976-256210	19760702
GB 1591089	Α	19810610	GI	3 1976-52720	19761217
CH 637380	Α	19830729		H 1977-16193	19771229
GB 2026471	Α	19800206	GI	3 1978-26429	19780606
GB 2026471	В2	19821027			
AT 7905697	Α	19800615	A.	r 1979-5697	19790824
AT 360538	В	19810112			
AT 7905698	Α	19800615	A.	1979-5698	19790824
AT 360539	В	19810112			
AT 7905696	A	19800615	A.	Г 1979-5696	19790824
AT 360537	В	19810112			
AT 8002722	A	19811115	A'	1980-2722	19800521
AT 367402	В	19820712			
US 4338322	A	19820706		3 1980-180905	19800825
US 4370334	A	19830125		5 1980-213048	19801204
FI 8103046	A	19810930	F]	1981-3046	19810930
FI 63022	В	19821231			
FI 63022	C	19830411		. 1001 5015	
DK 8105047	A	19811113	Di	1981-5047	19811113
DK 152285	В	19880215		,	
DK 152285	C	19881010	G.	* 1000 1550	1000000
CH 634051	A.	19830114		H 1982-1778	19820323
CH 634052	A	19830114		I 1982-1780	19820323
CH 637938	A	19830831		H 1982-1779	19820323
US 4525478 CH 638785	A n	19850625		1982-414842	19820903
DK 8403744	A n	19831014		1982-6326	19821029
DK 8403744 DK 152359	A	19840801	וע	1984-3744	19840801
DK 152359 DK 152359	В	19880222			
	С	19881010	CP 10	N75 27040	10750700
RITY APPLN. INFO.:				975-27945 975-20054	19750702
				975-39854 975-51524	19750929
				975-51524 976-13761	19751216
			GD 15	10-12/01	19760405

US	1976-701994	19760701
GB	1976-52720	19761217
US	1977-809788	19770624
GB	1978-26429	19780606
GB	1978-39978	19781010
СН	1976-8377	19760630
DK	1976-2981	19760701
FI	1976-1912	19760701
AT	1976-4856	19760702
CA	1977-256210	19770902
AT	1977-9018	19771216
CH	1977-15534	19771216
US	1979-39752	19790517
US	1980-213048	19801204

GΙ

Dihydropyridines I (R = optionally substituted Ph; R1, R2 = optionally substituted alkoxycarbonyl; R3 = hydroxyalkyl, gem-dialkoxyalkyl; R4 = H, alkyl, R3) were prepd. Thus 2-O2NC6H4CHO was treated with (EtO)2CHCOCH2CO2Et to give (EtO)2CHCOC(CO2Et):CHC6H4NO2-2 which was treated with Et 3-aminocrotonate to give II [R5 = CH(OEt)2]. Ketal cleavage gave II (R5 = CHO) which was reduced with NaBH4 to II (R5 = CH2OH). At 64 .mu.g/kg i.v. in dogs II (R5 = CHO, CH2OH) increased the coronary blood flow by 190 and 214%, resp.

IT 62759-96-0P 62759-98-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and ketal cleavage of)

RN 62759-96-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-(diethoxymethyl)-1,4-dihydro-6-methyl-4-(2-thienyl)-, diethyl ester (9CI) (CA INDEX NAME)

RN 62759-98-2 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-(diethoxymethyl)-4-(2-furanyl)-1,4-dihydro-6-methyl-, diethyl ester (9CI) (CA INDEX NAME)

10/022,874

IT 75530-33-5P 75535-91-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 75530-33-5 CAPLUS

CN [4,4'-Bipyridine]-3,5-dicarboxylic acid, 2-(dimethoxymethyl)-1,4-dihydro-6-methyl-, 3-methyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

RN 75535-91-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-(dimethoxymethyl)-1,4-dihydro-6-methyl-4-(2-thienyl)-, 3-methyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

L11 ANSWER 40 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1980:620594 CAPLUS

DOCUMENT NUMBER:

93:220594

TITLE:

 $\hbox{$2-$Methyldihydropyridine derivatives and pharmaceutical}\\$ 

composition containing it

INVENTOR(S):

Sato, Yoshinari

PATENT ASSIGNEE(S):

Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE:

Ger. Offen., 67 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE		APPL	ICATION NO.	DATE
DE 2940833	A1	19800430		DE 1	979-2940833	19791009
DE 2940833	C2	19890126				
СН 637380	Α	19830729		CH 1	977-16193	19771229
CA 1117117	A1	19820126		CA 1	979-336130	19790921
BE 879263	A1	19800408		BE 1	979-197526	19791008
FR 2438654	A1	19800509		FR 1	979-25007	19791008
FR 2438654	B1	19830114				
SE 7908367	Α	19800411		SE 1	.979-8367	19791009
SE 446265	В	19860825				
SE 446265	С	19861204				
NL 7907482	Α	19800414		NL 1	979-7482	19791009
JP 55062065	A2	19800510		JP 1	979-130530	19791009
JP 61025711	B4	19860617				
GB 2036722	А	19800702		GB 1	979-35022	19791009
GB 2036722	B2	19821201				
СН 642353	Α	19840413		CH 1	979-9128	19791010
SE 8400689	Α	19840209		SE 1	984-689	19840209
SE 446096	В	19860811				
JP 61118366	A2	19860605		JP 1	985-214152	19850926
JP 61043343	B4	19860926				
PRIORITY APPLN. INFO.:			GB	1978	-39978	19781010
			СН	1977	-15534	19771216
OTHER SOURCE(S):	CAS	SREACT 93:22	0594	1		

GI

$$\begin{array}{c|c} R^1 \\ R^2 O_2 C \\ \hline \\ Me \\ H \end{array} \qquad \begin{array}{c} CO_2 R^3 \\ R \\ I \end{array}$$

Dihydropyridinedicarboxylates I [R = CHO, dialkoxymethyl, CH2OH, cyano; R1 AΒ = (substituted) Ph, 4-pyridyl, 2-thienyl; R2 = CHMe2, CH2CH2R4 (R4 = Cl, PhO, HO, EtO, Me, PhCH2O, PhNMe); R3 = lower alkyl] and their salts were prepd. for use as vasodilators and antihypertensives (test data tabulated). Thus 3-O2NC6H4CH:C(CO2Me)COCH(OMe)2 was heated with H2NCMe: CHCO2CHMe2 to give I [R = CH(OMe)2, R1 = 3-O2NC6H4, R2 = CHMe2, R3

#### IT75530-33-5P 75535-91-0P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)

RN75530-33-5 CAPLUS

[4,4'-Bipyridine]-3,5-dicarboxylic acid, 2-(dimethoxymethyl)-1,4-dihydro-6methyl-, 3-methyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

75535-91-0 CAPLUS RN

3,5-Pyridinedicarboxylic acid, 2-(dimethoxymethyl)-1,4-dihydro-6-methyl-4-CN (2-thienyl)-, 3-methyl 5-(1-methylethyl) ester (9CI) (CA INDEX NAME)

L11 ANSWER 41 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

1979:557563 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 91:157563

TITLE: Bipyridines. Part X. A convenient synthesis of some

bipyridines and related compounds

AUTHOR(S): Balicki, Roman; Kaczmarek, Lukasz; Nantka-Namirski,

Pawel

CORPORATE SOURCE: Inst. Org. Chem., Pol. Acad. Sci., Warsaw, 01224, Pol.

SOURCE: Polish Journal of Chemistry (1979), 53(4), 893-9

CODEN: PJCHDQ; ISSN: 0137-5083

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 91:157563

GΙ

Bipyridines I (R = 2-, 3-, 4-pyridyl, 6-methyl-2-pyridyl, R1 = H) were AB prepd. by treating RCHO with EtO2CCH2COCO2Et, cyclizing RCH[CH(CO2Et)COCO2Et]2 with NH4OAc-HOAc, aromatizing to I (R1 = CO2Et), hydrolyzing the ester groups, and decarboxylating I (R1 = CO2H). II were obtained by treating the dihydropyridinetetracarboxylates with N2H4.

IT 71569-81-8P 71569-82-9P 71569-83-0P

71569-84-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and aromatization of)

RN 71569-81-8 CAPLUS

CN [4,4'-Bipyridine]-2,3,5,6-tetracarboxylic acid, 1,4-dihydro-, tetraethyl ester (9CI) (CA INDEX NAME)

RN 71569-82-9 CAPLUS

CN [3,4'-Bipyridine]-2',3',5',6'-tetracarboxylic acid, 1',4'-dihydro-, tetraethyl ester (9CI) (CA INDEX NAME)

RN 71569-83-0 CAPLUS

CN [2,4'-Bipyridine]-2',3',5',6'-tetracarboxylic acid, 1',4'-dihydro-, tetraethyl ester (9CI) (CA INDEX NAME)

RN 71569-84-1 CAPLUS

CN [2,4'-Bipyridine]-2',3',5',6'-tetracarboxylic acid, 1',4'-dihydro-6-methyl-

, tetraethyl ester (9CI) (CA INDEX NAME)

# IT 71569-85-2P 71569-86-3P 71569-87-4P 71569-88-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and decarboxylation of)

RN 71569-85-2 CAPLUS

CN [4,4'-Bipyridine]-2,3,5,6-tetracarboxylic acid, tetraethyl ester (9CI) (CA INDEX NAME)

RN 71569-86-3 CAPLUS

CN [3,4'-Bipyridine]-2',3',5',6'-tetracarboxylic acid, tetraethyl ester (9CI) (CA INDEX NAME)

RN 71569-87-4 CAPLUS

CN [2,4'-Bipyridine]-2',3',5',6'-tetracarboxylic acid, tetraethyl ester (9CI) (CA INDEX NAME)

71569-88-5 CAPLUS RN

[2,4'-Bipyridine]-2',3',5',6'-tetracarboxylic acid, 6-methyl-, tetraethyl CNester (9CI) (CA INDEX NAME)

L11 ANSWER 42 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1978:546772 CAPLUS DOCUMENT NUMBER:

TITLE:

89:146772

Pharmaceutical 2-position-substituted

1,4-dihydropyridine derivatives

INVENTOR(S): Bossert, Friedrich; Wehinger, Egbert; Meyer, Horst; Heise, Arend; Kazda, Stanislaus; Stoepel, Kurt;

Towart, Robertson; Vater, Wulf; Schlossmann, Klaus Bayer A.-G., Fed. Rep. Ger.

PATENT ASSIGNEE(S):

SOURCE:

Ger. Offen., 73 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT:

PA'	TENT NO.	KIND	DATE	APPLICATION NO. DAT	'E
DE	2658183	A1	19780706	DE 1976-2658183 197	61222
US	4188395	Α	19800212	US 1977-856559 197	71201
NL	7714074	Α	19780626	NL 1977-14074 197	71219
AU	7731708	A1	19790628	AU 1977-31708 197	71219
ΑU	516921	В2	19810702		
GB	1560280	A	19800206 .	GB 1977-52668 197	71219
IL	53639	A1	19811130	IL 1977-53639 197	71219
FI	7703867	A	19780623	FI 1977-3867 197	71220
JP	53079873	A2	19780714	JP 1977-152484 197	71220
JP	61031100	B4	19860717		
AT	7709129	Α	19800815	AT 1977-9129 197	71220
ΑT	361477	В	19810310		

CH	635323		Α	19830331		СН	1977-15687	19771220
BE	862107		A1	19780621		BE	1977-183669	19771221
SE	7714607		A	19780623		SE	1977-14607	19771221
DK	7705716		A	19780623		DK	1977-5716	19771221
FR	2378763		A1	19780825		FR	1977-38602	19771221
FR	2378763		В1	19800919				
ES	465290		A1	19780916		ES	1977-465290	19771221
CA	1105934		A1	19810728		CA	1977-293648	19771221
PRIORITY	APPLN.	INFO.:			DE	197	76-2658183	19761222
GT								

Dihydropyridines I (R = H, alkyl, alkoxyalkyl, aralkyl; X = alkylene; R1 = alkylthio, carboxylic ester, phthalimido; R2, R4 = CO2R6, COR6, SR6, SOR6, SO2R6; R3 = aryl with 1-3 substituents, optionally substituted heterocyclic, aralkyl, cycloalkyl, cycloalkenyl, or styryl; R5 = H, alkyl, XR1; R6 = alkyl, alkenyl, alkynyl, alkoxyalkyl, hydroxyalkyl, aminoalkyl, alkylaminoalkyl, aralkyl) were prepd. for use as coronary vasodilators, antihypertensives, muscle relaxants, anticholesteremics and antifibrillatory reagents (no data). Thus, 2-formylpyridine was condensed with MeSCH2COCH2CO2Et and H2NCMe:CHCO2Et to give 50% II.

### IT 67429-05-4P 67429-16-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 67429-05-4 CAPLUS

CN [2,4'-Bipyridine]-3',5'-dicarboxylic acid, 2'-[(acetyloxy)methyl]-1',4'-dihydro-6'-methyl-, diethyl ester (9CI) (CA INDEX NAME)

RN 67429-16-7 CAPLUS

CN [3,4'-Bipyridine]-3',5'-dicarboxylic acid, 2'-[(acetyloxy)methyl]-1',4'-dihydro-6'-methyl-, diethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 43 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1977:189726 CAPLUS

DOCUMENT NUMBER:

86:189726

TITLE:

1,4-Dihydropyridine derivatives

Sato, Yoshinari INVENTOR(S):

PATENT ASSIGNEE(S):

Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: Ger. Offen., 133 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT:

PATENT NO.	KIND	DATE	AP	PLICATION NO.	DATE
DE 2629892	A1	19770127	DE	1976-2629892	19760702
GB 1552911	A	19790919	GB	1975-27945	19750702
BE 843576	A1	19761229	BE	1976-168458	19760629
CH 629778	A	19820514	CH	1976-8377	19760630
FI 7601912	А	19770103	FI	1976-1912	19760701
FI 61696	В	19820531			
FI 61696	С	19820910			
DK 7602981	А	19770103	DK	1976-2981	19760701
SE 7607566	Α	19770103	SE	1976-7566	19760701
SE 434049	В	19840702			
SE 434049	С	19841011			
CS 189011	P	19790330	CS	1976-4356	19760701
CS 189047	P	19790330	CS	1977-2596	19760701
CS 189048	P	19790330	CS	1977-2597	19760701
CS 189049	P	19790330	CS	1977-2598	19760701
CS 189050	P	19800229	CS	1977-2599	19760701
NL 7607338	А	19770104	NL	1976-7338	19760702
NL 190812	В	19940405			
NL 190812	С	19940901			
JP 52005777	A2	19770117	JP	1976-79413	19760702
JP 59048827	В4	19841129			
FR 2315930	<b>A</b> 1	19770128	FR	1976-20392	19760702
FR 2315930	B1	19781117			
DD 126722	С	19770810		1976-193705	19760702
HU 173063	P	19790228		1976-FU342	19760702
HU 173064	P	19790228	HU	1976-FU350	19760702
HU 173195	P	19790328	HU	1976-FU353	19760702
HU 173193	P	19790328	HU	1976-FU351	19760702
HU 173194	P	19790328	HU	1976-FU352	19760702
AT 7604856	Α	19800615	AT	1976-4856	19760702
AT 360531	В	19810112			
AU 510353	B2	19800619		1976-15547	19760702
CA 1080223	A1	19800624	CA	1976-256210	19760702

CH	637380	A	19830729		СН	1977~16193	19771229
	7905697	A	19800615			1979-5697	19790824
	360538	В	19810112				
	7905698	Ā	19800615		ΑТ	1979-5698	19790824
	360539	В	19810112				
	7905696	Α	19800615		ΑT	1979-5696	19790824
	360537	В	19810112				
FI	8103046	A	19810930		FI	1981-3046	19810930
FI	63022	В	19821231				
FI	63022	С	19830411				
DK	8105047	Α	19811113		DK	1981-5047	19811113
DK	152285	В	19880215				
	152285	С	19881010				
	634051	Α	19830114			1982-1778	19820323
	634052	A	19830114			1982-1780	19820323
	637938	A	19830831			1982-1779	19820323
	59231017	A2	19841225		JР	1984-91231	19840507
	60012324	B4	19850401				10040505
	60001154	A2	19850107		JР	1984-91232	19840507
	61009300	B4	19860322			1004 2744	30040001
	8403744	A	19840801		DK	1984-3744	19840801
	152359	В	19880222				
	152359	С	19881010	C D	10'	75-27945	19750702
PRIORIT	Y APPLN. INFO.:					75-27945 75-39854	19750702
						75-59654 75-51524	19751216
						76-13761	19760405
						76-13701 76-8377	19760630
						76-2981	19760701
				FI		76-1912	19760701
					_	76-4856	19760702
						76-52720	19761217
						77-256210	19770902
						77-15534	19771216
OTHER S	OURCE(S):	CA	SREACT 86:18				

GI

Vasodilator and antihypertensive title compds., including I (R = Et, R1 = NO2, R2 = CHO, CH2OH; R = Et, R1 = Cl, R2 = CH2OH; R = CH2CH2NMeCH2Ph, R1 = NO2, R2 = CN) were prepd. Thus, I (R = Et, R1 = NO2, R2 = CHO) was obtained by treating 2-O2NC6H4CHO with (EtO)2CHCOCH2CO2Et, treating (EtO)2CHCOC(:CHC6H4NO2-2)CO2Et with H2NCMe:CHCO2Et, and hydrolyzing I [R2 = CH(OEt)2]. At 64 mg/kg i.v. in dogs, I (R = Et, R1 = NO2, R2 = CHO) gave 190% increase in coronary blood flow over controls.

#### IT 62759-96-0P 62759-98-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and hydrolysis of)

RN 62759-96-0 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 2-(diethoxymethyl)-1,4-dihydro-6-methyl-4-

(2-thienyl)-, diethyl ester (9CI) (CA INDEX NAME)

62759-98-2 CAPLUS RN

3,5-Pyridinedicarboxylic acid, 2-(diethoxymethyl)-4-(2-furanyl)-1,4-CN dihydro-6-methyl-, diethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 44 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1976:432859 CAPLUS

DOCUMENT NUMBER:

85:32859

TITLE:

2,3,5,6-Tetracarboxy-4-pyridyl-1,4-dihydropyridine

derivatives

INVENTOR(S):

Bossert, Friedrich; Meyer, Horst; Vater, Wulf

PATENT ASSIGNEE(S):

SOURCE:

Bayer A.-G., Fed. Rep. Ger. U.S., 16 pp. Division of U.S. 3,905,983.

CODEN: USXXAM

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT: 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3946028	А	19760323	US 1974-524090	19741115
DE 2248150	A1	19740404	DE 1972-2248150	19720930
US 3905983	А	19750916	US 1973-399850	19730924
PRIORITY APPLN.	INFO.:		DE 1972-2248150	19720930
			US 1973-399850	19730924

$$R^{4}O_{2}C$$
 $R^{5}$ 
 $R^{5}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{1}$ 

Pyridinecarboxylates I [R = H, R1 = Me, Et, CO2Et, CO2H, CH2CO2Me, CH2CO2Et, R2 = Me, Et, R3 = pyridyl, .alpha.-naphthyl, styryl, CH2CH2Ph, C6H5-nR6n [R6n = NO2, CF3, (MeO)3, (CF3)2, Cl, MeS, Ph, N3], R4 = Me, Et, R5 = CO2Et, CO2H, CH2CO2Et; R = R1 = R2 = Me, R3 = 3-O2NC6H4, R4 = Et, R5 = CO2Et] (49 compds.), useful as coronary dilators at 0.1-10 mg/kg i.v. (dogs), were prepd. (in cases where R1 and R5 .noteq. CO2H) by 5 methods with 35-90% yields. Thus, 2-pyridinecarboxaldehyde, MeCOCH2CO2Me, and (MeO2CCH2)2C:NH in EtOH refluxed several hr gave 60% I (R = H, R1 = R2 = R4 = Me, R3 = 2-pyridyl, R5 = CH2CO2Me). I [R1 and(or) R5 = CO2H] were prepd. by partial sapon. of the corresponding esters for several hr with Na in refluxing EtOH.

IT 52603-83-5P 52603-84-6P 52603-86-8P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and coronary dilation activity of)

RN 52603-83-5 CAPLUS

CN [2,4'-Bipyridine]-2',3',5'-tricarboxylic acid, 1',4'-dihydro-6'-methyl-, 2',3'-diethyl 5'-methyl ester (9CI) (CA INDEX NAME)

RN 52603-84-6 CAPLUS

CN [3,4'-Bipyridine]-2',3',5'-tricarboxylic acid, 1',4'-dihydro-6'-methyl-, triethyl ester (9CI) (CA INDEX NAME)

RN 52603-86-8 CAPLUS
CN [2,4'-Bipyridine]-2',3',5'-tricarboxylic acid,

[2,4'-Bipyridine]-2',3',5'-tricarboxylic acid, 1',4'-dihydro-6'-methyl-,

triethyl ester (9CI) (CA INDEX NAME)

ΙT 52603-85-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

52603-85-7 CAPLUS RN

[4,4'-Bipyridine]-2,3,5-tricarboxylic acid, 1,4-dihydro-6-methyl-, CN triethyl ester (9CI) (CA INDEX NAME)

CAPLUS COPYRIGHT 2004 ACS on STN L11 ANSWER 45 OF 47

ACCESSION NUMBER:

1976:432858 CAPLUS

DOCUMENT NUMBER:

85:32858

TITLE:

3,5,6-Tricarboxy-4-pyridyl-1,4-dihydropyridine

derivatives

INVENTOR(S):

Bossert, Friedrich; Meyer, Horst; Vater, Wulf

Bayer A.-G., Fed. Rep. Ger.

PATENT ASSIGNEE(S): SOURCE:

U.S., 17 pp. Division of U.S. 3,905,983.

CODEN: USXXAM

DOCUMENT TYPE:

Patent English

LANGUAGE:

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3946027 DE 2248150 US 3905983	A Al A	19760323 19740404 19750916	US 1974-523967 DE 1972-2248150 US 1973-399850	19741115 19720930 19730924
PRIORITY APPLN. INFO.	• •	19730310	DE 1972-2248150 US 1973-399850	19720930 19730924

GΙ

$$R^{4}O_{2}C$$
 $R^{5}$ 
 $R^{1}$ 
 $R^{1}$ 
 $R^{1}$ 

Pyridinecarboxylates I [R = H, R1 = Me, Et, CO2Et, CO2H, CH2CO2Me, CH2CO2Et, R2 = Me, Et, R3 = pyridyl, .alpha.-naphthyl, styryl, CH2CH2Ph, C6H5-nR6n [R6n = NO2, CF3, (MeO)3, (CF3)2, Cl, MeS, Ph, N3], R4 = Me, Et, R5 = CO2Et, CO2H, CH2CO2Et; R = R1 = R2 = Me, R3 = 3-O2NC6H4, R4 = Et, R5 = CO2Et] (49 compds.), useful as coronary dilators at 0.1-10 mg/kg i.v. (dogs), were prepd. (in cases where R1 and R5 .noteq. CO2H) by 5 methods with 35-90% yields. Thus, 2-pyridinecarboxaldehyde, MeCOCH2CO2Me, and (MeO2CCH2)2C:NH in EtOH refluxed several hr gave 60% I (R = H, R1 = R2 = R4 = Me, R3 = 2-pyridyl, R5 = CH2CO2Me). I [R1 and(or) R5 = CO2H] were prepd. by partial sapon. of the corresponding esters for several hr with Na in refluxing EtOH.

IT 52603-86-8P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and coronary dilation activity of)

RN 52603-86-8 CAPLUS

CN [2,4'-Bipyridine]-2',3',5'-tricarboxylic acid, 1',4'-dihydro-6'-methyl-, triethyl ester (9CI) (CA INDEX NAME)

IT 52603-83-5P 52603-84-6P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and coronary dilation of)

RN 52603-83-5 CAPLUS

CN [2,4'-Bipyridine]-2',3',5'-tricarboxylic acid, 1',4'-dihydro-6'-methyl-, 2',3'-diethyl 5'-methyl ester (9CI) (CA INDEX NAME)

#### 10/022,874

RN 52603-84-6 CAPLUS

CN [3,4'-Bipyridine]-2',3',5'-tricarboxylic acid, 1',4'-dihydro-6'-methyl-, triethyl ester (9CI) (CA INDEX NAME)

IT 52603-85-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of)

RN 52603-85-7 CAPLUS

CN [4,4'-Bipyridine]-2,3,5-tricarboxylic acid, 1,4-dihydro-6-methyl-, triethyl ester (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & \\ & & \\ & \\ & & \\$$

L11 ANSWER 46 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1975:156107 CAPLUS

DOCUMENT NUMBER:

82:156107

TITLE:

2-(Alkoxyalkyl)-1,4-dihydro-3,5-pyridine dicarboxylate

pharmaceuticals

INVENTOR(S):

Bossert, Friedrich; Wehinger, Egbert; Vater, Wulf;

Stoepel, Kurt

PATENT ASSIGNEE(S):

Bayer A.-G.

SOURCE:

Ger. Offen., 54 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

Patent

LANGUAGE:

German

FAMILY ACC. NUM. COUNT: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<b></b>			<del>-</del>	
DE 2335466	<b>A</b> 1	19750130	DE 1973-2335466	19730712
AU 7470969	<b>A</b> 1	19760108	AU 1974-70969	19740708
FI 7402120	Α	19750113	FI 1974-2120	19740710
NL 7409344	Α	19750114	NL 1974-9344	19740710
JP 50040578	A2	19750414	JP 1974-78370	19740710

JР	60011030	B4	19850322				
DD	118631	С	19760312	D	D	1974-179837	19740710
AT	7405696	A	19761115	A	$\mathbf{T}$	1974-5696	19740710
AT	337699	В	19770711				
$_{ m PL}$	91873	P	19770331	P	L	1974-183228	19740710
$_{ m PL}$	94266	P	19770730	P	L	1974-172611	19740710
BE	817540	A1	19750113	В	βE	1974-146464	19740711
SE	7409146	A	19750113	S	Έ	1974-9146	19740711
DK	7403739	A	19750303	D	ΣK	1974-3739	19740711
ZA	7404461	A	19750730	Z	Ά	1974-4461	19740711
GB	1436289	Α	19760519	G	βB	1974-30746	19740711
ES	428185	<b>A</b> 1	19761216	E	S	1974-428185	19740711
CH	614196	Α	19791115	C	CH	1974-9603	19740711
FR	2236497	<b>A</b> 1	19750207	F	rR	1974-24425	19740712
US	3974278	Α	19760810	U	JS	1975-576724	19750512
ES	448396	A1	19770916	E	ES	1975-448396	19750531
ES	448395	A1	19770916	E	ES	1975-448395	19750531
US	4020178	Α	19770426	U	JS	1975-585963	19750611
US	3971796	Α	19760727	U	JS	1975-609153	19750829
ES	448394	A1	19770716	E	ES	1976-448394	19760531
ES	448397	A1	19770801	E	ES	1976-448397	19760531
CH	615915	A	19800229			1977-12220	19771006
CH	622507	A	19810415	C	CH	1977-12410	19771011
JP	57131763	A2	19820814	J	JΡ	1982-454	19820106
JP	59043951	B4	19841025				
JР	57131764	A2	19820814	J	JΡ	1982-455	19820106
JP	59043952	B4	19841025				
PRIORITY	APPLN. INFO.:					3-2335466	19730712
				US 1	97	4-485300	19740702
				CH 1	.97	4-9603	19740711

GI For diagram(s), see printed CA Issue.

AB Coronary vasodilator pyridinedicarboxylates I (R = Me, Et, CH2OMe, CH2OEt, CO2Et, CO2H, CH2CO2Et, CHMe2,; R1 = substituted phenyl, 2-pyridyl, 3-pyridyl, 2-dimethylamino-5-pyrimidinyl; R2 = Et, CHMe2) were prepd. Thus, reaction of PhCHO with EtoCH2CO2COCH2CO2Et and H2CMe: CNCO2Et with 65% I (R = Me, R1 = Ph, R2 = Et), which at 1 mg/kg i.v. in anesthetized dogs maintained increased O satn. in the coronary sinus for 20 min.

IT 55551-47-8P 55551-50-3P 55551-55-8P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. and coronary vasodilating activity of)

RN 55551-47-8 CAPLUS

CN [2,4'-Bipyridine]-3',5'-dicarboxylic acid, 1',4'-dihydro-2'-methyl-6'-[(1-methylethoxy)methyl]-, diethyl ester (9CI) (CA INDEX NAME)

RN 55551-50-3 CAPLUS

CN 3,5-Pyridinedicarboxylic acid, 4-[2-(dimethylamino)-5-pyrimidinyl]-2-(ethoxymethyl)-1,4-dihydro-6-methyl-, diethyl ester (9CI) (CA INDEX NAME)

RN 55551-55-8 CAPLUS
CN [2,4'-Bipyridine]-3',5'-dicarboxylic acid, 2',6'-bis(ethoxymethyl)-1',4'-dihydro-, diethyl ester, monohydrochloride (9CI) (CA INDEX NAME)

● HCl

IT 55551-51-4P 55551-62-7P 55551-63-8P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)

RN 55551-51-4 CAPLUS

CN [2,4'-Bipyridine]-3',5'-dicarboxylic acid, 2'-(ethoxymethyl)-1',4'-dihydro-6'-methyl-, diethyl ester (9CI) (CA INDEX NAME)

RN 55551-62-7 CAPLUS

CN [3,4'-Bipyridine]-3',5'-dicarboxylic acid, 2'-(2-ethoxy-2-oxoethyl)-1',4'-dihydro-6'-(methoxymethyl)-, diethyl ester (9CI) (CA INDEX NAME)

RN 55551-63-8 CAPLUS

CN [2,4'-Bipyridine]-3',5'-dicarboxylic acid, 1',4'-dihydro-2'- (methoxymethyl)-6'-(1-methylethyl)-, diethyl ester (9CI) (CA INDEX NAME)

L11 ANSWER 47 OF 47 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER:

1974:403773 CAPLUS

DOCUMENT NUMBER:

81:3773

Patent

TITLE:

4-Aryl-1,4-dihydropyridinepolycarboxylates Bossert, Friedrich; Meyer, Horst; Vater, Wulf

INVENTOR(S):
Bossert,

PATENT ASSIGNEE(S): Bayer A.-G.

SOURCE:

Ger. Offen., 45 pp.

CODEN: GWXXBX

DOCUMENT TYPE:

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 3

PATENT NO.	KIND	DATE	APPLICATION NO. DATE
DE 2248150	A1	19740404	DE 1972-2248150 1972093
US 3905983	Α	19750916	US 1973-399850 1973092
CA 1005061	A1	19770208	CA 1973-181860 1973092
AU 7360716	A1	19750327	AU 1973-60716 1973092
DD 110659	С	19750112	DD 1973-173732 1973092
SE 403777	С	19781214	SE 1973-13187 1973092
NL 7313422	A	19740402	NL 1973-13422 1973092
FR 2201095	A1	19740426	FR 1973-34944 1973092
JP 49070977	A2	19740709	JP 1973-108627 1973092
JP 56047905	В4	19811112	
ZA 7307659	Α	19740828	ZA 1973-7659 1973092
ни 166357	P	19750328	HU 1973-BA2984 1973092
GB 1389509	Α	19750403	GB 1973-45481 1973092
AT 7308347	А	19750915	AT 1973-8347 1973092
AT 330175	В	19760625	
СН 583703	A	19770114	СН 1973-13902 1973092
DK 137722	С	19781002	DK 1973-5334 1973092

СН	605752		Α	19781013		СН	1976-11137	19730928
ES	419193		A1	19761216		ES	1973-419193	19730929
PL	91085		P	19770228		$_{ m PL}$	1973-165524	19730929
$\mathtt{PL}$	92084		P	19770331		PL	1973-182552	19730929
$\mathtt{PL}$	92079		P	19770331		PL	1973-182553	19730929
CS	178441		P	19770915		CS	1973-5597	19731001
CS	178435		P	19770915		CS	1973-6765	19731001
CS	178440		P	19770915		CS	1975-5596	19731001
US	3943140		Α	19760309		US	1974-523982	19741115
US	3946028		Α	19760323		US	1974-524090	19741115
US	3946027		A	19760323		US	1974-523967	19741115
ES	443522		A1	19770501		ES	1975-443522	19751216
ES	443521		A1	19770516		ES	1975-443521	19751216
CH	601233		A	19780630		СН	1977-5381	19770928
PRIORITY	Y APPLN.	INFO.:			DE	197	2-2248150	19720930
					US	197	73-399850	19730924

GI For diagram(s), see printed CA Issue.

AB Nineteen pyridinepolycarboxylates I (R = 2-, 3-, or 4-pyridyl, substituted Ph, or 1-naphthyl; R1, R2 = Me or Et; R3 = CH2CO2Me, CO2Et, CH2CO2Et, or CO2H; R4 = Me, CH2CO2Et, CO2Et, or CH2CO2Me) were prepd. by various methods and used as coronary dilators and for increasing the O supply to the heart. Thus, refluxing 2-pyridinecarboxaldehyde (II), MeCOCH2CO2Me, and di-Me .beta.-iminoglutarate in EtOH gave 60% I (R = 2-pyridyl, R1 = R2 = Me, R3 = CH2CO2Me, R4 = Me), which was also prepd. in 57% yield by heating II, di-Me acetonedicarboxylate, and Me .beta.-aminocrotonate in EtOH. Refluxing 3-O2NC6H4CHO, Et .beta.-aminocrotonate, and (EtO2C)2 in EtOH gave 62% I (R = 3-O2NC6H4, R1 = R2 = Et, R3 = CO2Et, R4 = Me) (III). Re-fluxing III in EtOH contg. Na gave 90% I (R = 3-O2NC6H4, R1 = R2 = Et, R3 = CO2H, R4 = Me).

# IT 52603-83-5P 52603-84-6P 52603-85-7P 52603-86-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)

RN 52603-83-5 CAPLUS

CN [2,4'-Bipyridine]-2',3',5'-tricarboxylic acid, 1',4'-dihydro-6'-methyl-, 2',3'-diethyl 5'-methyl ester (9CI) (CA INDEX NAME)

RN 52603-84-6 CAPLUS

RN 52603-85-7 CAPLUS

CN [4,4'-Bipyridine]-2,3,5-tricarboxylic acid, 1,4-dihydro-6-methyl-, triethyl ester (9CI) (CA INDEX NAME)

RN 52603-86-8 CAPLUS

CN [2,4'-Bipyridine]-2',3',5'-tricarboxylic acid, 1',4'-dihydro-6'-methyl-, triethyl ester (9CI) (CA INDEX NAME)